口蹄疫基因工程疫苗重组策略的探讨
|
摘要
口蹄疫(foot-and-mouth disease，FMD)是由口蹄疫病毒(foot-and-mouth diseasevirus，FMDV)引起的烈性传染病，主要感染偶蹄目动物。除动物死亡造成直接经济损失外，动物在患病期间肉和奶的生产停止导致该地区甚至该国家的畜产品进出口贸易停止，也造成巨大的经济损失。因此，世界各国都很重视本病的防制。
FMD弱毒疫苗和灭活疫苗等常规疫苗都具有良好的免疫原性，在预防和控制FMD的过程中发挥着重要作用，但由于病毒毒力返强、病毒灭活不彻底、活病毒逃逸疫苗加工厂等不安全因素。促使人们寻求一种更加安全有效的FMD疫苗。近年来，随着分子生物学技术的飞速发展，FMD基因工程疫苗等多种新型的疫苗都在不断的研究开发中，并取得了很好的成绩，但存在的问题是价格昂贵和动物保护试验不尽如人意。因此，研究者试图从多方面增强FMD疫苗的免疫效果，其中用细胞因子作为分子免疫佐剂，已引起众多研究者的关注。研究表明，许多细胞因子具有明显的免疫佐剂效应，可增强机体对抗原的反应性或增强抗原的免疫原性。细胞因子在体内缓慢而持久地释放，不会对机体产生毒性作用。具有佐剂效应的细胞因子有干扰素(IFN-α、IFN-β、IFN-γ)；淋巴因子(IL-2、IL-3、IL-4、IL-5、IL-10等)；单核因子(IL-1、IL-6、IL-8、IL-12等)及其它细胞因子。
本研究的目的是通过酵母表达系统和非复制型腺病毒载体系统表达口蹄疫病毒抗原基因及共表达抗原基因和免疫佐剂，研究免疫佐剂对重组蛋白和重组病毒的免疫增强作用，为口蹄疫基因工程疫苗的研究探索新的途径。研究主要从以下几个方面展开。
1．人工合成O型口蹄疫病毒VP1-2A基因，并克隆到pMDl8-T载体中，命名为pMD18-VP1-2A(上海Invitrogen公司完成)，以pMD18-VP1-2A为模板，设计一对引物，PCR扩增VP1基因，亚克隆到pET-32a(+)中，构建了表达载体pET-VP1，通过IPTG诱导表达，实现了融合蛋白VP1在大肠杆菌中的高效表达，表达融合蛋白为44kD左右，Western-blot试验表明，该重组蛋白具有免疫反应性。以纯化的重组VP1蛋白作为包被抗原，抗原最佳包被浓度确定为10.56μg／ml，能明显的区分口蹄疫病毒的阴阳性血清，建立了检测FMDV抗体的ELISA方法，为后期的研究打下基础。
2．人工合成O型口蹄疫病毒的多表位基因，并克隆到pMD18-T载体中，命名为pMD18-EG(上海Invitrogen公司完成)。另外，以含有人结核杆菌HSP70基因的质粒(pMD18-HSP70)为模板，设计引物PCR扩增HSP70基因。将目的基因克隆到酵母表达载体pPICZaA中，先后构建四个酵母表达载体pPICZaA-EG、pPICZaA-VP1、pPICZaA-EG-HSP70、pPICZaA-VP1-HSP70。通过电穿孔法将四个表达载体转化到酵母菌X-33中，用Zeocin~+平板筛选重组子，甲醇诱导表达，经SDS-PAGE电泳鉴定四个重组蛋白的大小分别约为23kD(rVP1)，20kD(rEG)，89kD(rEG-HSP70)，92kD(rVP1-HSP70)，免疫印迹分析后表明重组蛋白均具有免疫反应性。将四个重组蛋白以皮下接种的方式给小鼠进行3次免疫，同时设两组对照组小鼠，分别免疫PBS和常规灭活疫苗，然后通过测定IgG、IgGl、IgG2a、淋巴细胞增殖功能和IL-4、IFN-γ水平来衡量重组蛋白的免疫效果。结果表明重组蛋白既能诱导细胞免疫应答又能诱导体液免疫应答，rEG-HSP70产生的抗体与常规灭活苗相当，而细胞免疫水平从高到低依次为rEG-HSP70，rVP1-HSP70，灭活疫苗，rEG，rVP1。提示，HSP70作为分子佐剂在口蹄疫基因工程疫苗的研究中具有潜在的应用前景，为口蹄疫基因工程疫苗的研究提供一种新的思路。
3．重新设计引物扩增VPl和多表位基因，在多表位基因中加入通用型辅助性T淋巴细胞表位(PADRE)，并命名为EGS，分别将VP1和EGS基因克隆到腺病毒的穿梭载体pAdenoVator-CMV5-IRES-GFP中。得到的阳性穿梭质粒经PmeⅠ酶线性化后，利用电转化技术将线性化的质粒与腺病毒骨架载体pAdeno Vator△E1／E3共转化大肠杆菌BJ5183感受态细胞，使其在大肠杆菌中进行同源重组。将筛选到的重组病毒质：粒经PacⅠ酶线性化后暴露出包装信号，通过脂质体Lipofectamine ~(TM)2000转染293A细胞后得到重组病毒。利用报告基因GFP检测病毒滴度和感染效率，重组病毒rAd5-EGS和rAd5-VP1的滴度分别为10~(10.62)个TCID_(50)／ml和10~(11.87)个TCID_(50)／ml，重组病毒经过连续五代传代后效价稳定。通过PCR和western-blot证实FMDV V1l及表位基因得到成功的表达并有很好的免疫反应性。
4．分别以质粒pMD18-VP1-2A和以含有猪白细胞介素-2基因(PoIL-2)的质粒pMD18-PoIL-2为模板，PCR扩增VP1-2A和poIL-2基因，分别亚克隆到腺病毒的穿梭载体pAdenoVator-CMV5-IRES-GFP中。分别得到的阳性穿梭质粒pAd5polL-2和pAd5VP1-2A-PolL-2，经PmeⅠ酶线性化后，利用电转化技术将线性化的质粒与腺病毒骨架载体pAdenoVator△E1／E3共转化大肠杆菌BJ5183感受态细胞，使其在大肠杆菌中：进行同源重组。将筛选到的重组病毒质粒经PacⅠ酶线性化后暴露出包装信号，通过脂质体Lipofectamine ~(TM)2000转染293A细胞后得到重组病毒。Western-blot试验证实在FMDV 2A蛋白的介导下VP1-2A-PoIL-2裂解为VP1-2A和PoIL-2。同时，用淋巴细胞增殖试验分析单独表达PoIL-2和串联表达VP1-2A-poIL-2均具有刺激淋巴细胞增殖的生物活性。
5．以含有猪IFN-a基因的质粒pMD18-poIFN-a为模板，PCR扩增出poIFN-a基因，克隆到含有VP1-2A基因的腺病毒的穿梭载体pAdeno Vator-CMV5-IRES-GFP中。得到的阳性穿梭质粒pAd5VP1-2A-POIFN-a，经PmeⅠ酶线性化后，利用电穿孔法将其与腺病毒骨架载体pAdenoVator△E1／E3共转化大肠杆菌BJ5183感受态细胞，使其在大肠杆菌中进行同源重组。将筛选到的重组病毒质粒经PacⅠ酶线性化后暴露出包装信号，通过脂质体Lipofectamine ~(TM)2000转染293A细胞后得到重组病毒。Western-blot证实VP1-2A-PoIFN-a得到了表达，并在FMDV 2A蛋白的介导下VP1-2A-PoIFN-a裂解为VP1-2A和POIFN-a。细胞病变抑制法测定结果表明，重组猪a-干扰素具有较高抗病毒活性，10~5U／ml。
6．6周龄小鼠随机分为14组，每组12只。将6个重组病毒rAd5VP1、rAd5EGS、rAd5poIL-2、rAd5poIFN-a、rAd5VP1-2A-poIFN-a，rAd5VP1-2A-poIL-2分别以腹膜内接种的方式给小鼠进行3次免疫，同时设两组对照组小鼠，分别免疫PBS和常规灭活疫苗。然后通过测定IgG、IgG1、IgG2a、淋巴细胞增殖功能和IL-4、IFN-γ水平来衡量重组病毒的免疫效果。结果表明重组病毒既能诱导细胞免疫应答又能诱导体液免疫应答，rAd5VP1-2A-poIFN-a，rAd5VP1-2A-poIL-2免疫组的效果更优于其它免疫组，证实细胞因子发挥了明显的免疫佐剂效应。也进一步证实我们选用口蹄疫病毒2A蛋白介导细胞因子表达是正确的，因为只有2A发挥了有效的裂解作用，才能避免细胞因子在其氨基端融合其他蛋白而使构象发生改变，构象的改变可能会使它的功能和活性受到影响。抗体亚型测定结果显示，重组病毒既能诱导IgG1的分泌又能诱导IgG2a的分泌，但以IgG1为主。同时细胞因子ELISA试验结果进一步表明重组病毒主要刺激Th2分化(IL-4)，刺激Th1(γ-IFN)的分化的能力相对弱些。
以上实验证明，选择口蹄疫病毒2A蛋白酶介导口蹄疫病毒抗原基因与免疫佐剂在非复制型腺病毒载体表达系统中进行串联表达的设计思路是合理的，为口蹄疫基因工程疫苗的研究提供新的思路和见解。
Foot-and-mouth disease (FMD) was caused by FMDV, is a highly contagious, acute vesicular disease of cloven-hoofed animals, and is responsible for large economic losses, both as a direct result of the disease, and because of the necessary restrictions imposed on animal products and trade for disease control. Many researchers in the world pay attention to prevent and control this disease.
Although both of attenuated FMD vaccine and inactivated vaccine are effective, major problems were encountered such as unpredictable virulence in the field, high-containment vaccine production facilities, carried a slight risk of residual contamination of inactivated vaccines with live virus. Its use would most probably complicate the discrimination of naturally infected and vaccinated animals. Several novel approaches to vaccine development are emerging, and these may enjoy significant advantages over conventional vaccines. However, as yet they remain too costly for general veterinary use, and their immunogenicity is often limited. One way to remove this shortcoming is to improve the adjuvants used in the formulation of the vaccine. In general, there are some potent adjuvants, such as interferon(IFN-a、IFN-β、IFN-γ); lymph cytokines(IL-2、IL-3、IL-4、IL-5、IL-10); monocytines(IL-1、IL-6、IL-8、IL-12) and other cytokines.
In this study, the antigen of FMDV and some adjuvants (HSP70, PoIL-2, PoIFN-a) were co-expressed in methylotrophic yeast expression system and adenovirus vector expression system respectively. The affection of adjuvants on FMDV recombinant gene-engineering vaccine in mice was detected. This will provide novel ways for study of foot-and-mouth newly vaccine. All studies were listed as below:
1. VP1-2A gene of FMDV type O was synthesized and cloned into pMD18-T, named pMD18-VP1-2A (It had been done by Shanghai Invitrogen company) . VP1 gene was amplified from pMD18-VP1-2A and subcloned to pET-32a(+), named pET-VP1, recombinant VP1 was expressed in E.coli induced with IPTG. Recombinant protein was testified by SDS-PAGE, and which was expressed successfully and relative molecular mass was about 44kD. Western-blot result indicated that the recombinant protein had specific immunogenic characteristic against antibody of FDMV. ELISA test indicated that 10.56μg/ml of purified recombinant VP1 protein was coated as antigen can distinguish positive serum and negative serum of FMDV. This study was the basic for further study.
2. Multi-epitopes genes of 0 type foot-and-mouth diseases virus was synthesized and cloned into pMD18-T and named pMD18-EG (It had been done by Shanghai Invitrogen company). M.tuberculosis HSP70 gene was amplified from pMD18-HSP70. VP1 gene, EG gene and HSP70 gene were cloned into yeast expression vector pPICZaA. Four recombinant vectors were constructed and named pPICZaA-EG、pPICZaA-VP1、pPICZaA-EG-HSP70、pPICZaA-VP1-HSP70 respectively. Recombinant vector were transformed into methylotrophic yeast Pichia pastoris X-33 by electrophoration. The recombinant transformants were selected by Zeocin and induced by the addition of methanol every 24 h. The result of SDS-PAGE indicated that the recombinant proteins were successfully expressed in methylotrophic yeast Pichia pastoris and relative molecular mass were about 23kD(rVP1), 20kD(rEG), 89kD(rEG-HSP70), 92kD(rVP1-HSP70). Western blotting indicated that four recombinant proteins had specific antigenicity of FDMV. Mice were inoculated transcutaneous three times at a two-week interval with fusion protein, PBS and conventional inactivated vaccines. Level of IgG、IgG1、IgG2a、IL-4、IFN-γand proliferation T lymphocyte test were detected to evaluate humoral immune and cellular immune responses. The results indicated that fusion protein could elicit specific humoral immune and cellular immune responses. Compared with conventional inactivated vaccines, fusion protein elicited close to FMDV antibody level. Cellular immune responses in turn is rEG-HSP70, rVP1-HSP70, inactivated vaccine, rEG, rVP1, which suggest that HSP70 as molecular adjuvant can improve the immunogenicity of FMDV recombinant vaccine, thus provide valuable support for further development of FMDV genetic engineering vaccines.
3. VP1 gene and multi-epitopes gene were synthesized and cloned into pAdeno Vator-CMV5-IRES-GFP, named pA5-EGS and pA5-VP1 respectively. pA5-EGS and pA5-VP1 were Linearized by Pme I, and then linearized vector and pAdeno VatorΔE1/E3 co-transformed into E.coli BJ5183 competent cells by electrophoration. The homologous recombinant plasmids pAd5-EGS and pAd5-VP1 were selected and Linearized by Pac I to expose the encapsidation signal. Linearized virus plasmids were transfected into 293A cells by Lipofectamine ~(TM)2000, and recombinant viruses were named rAd5-EGS and rAd5-VP1. Infection titer and rate were evaluated through monitoring green fluorescent protein (GFP) expression. The filter of rAd5-EGS and rAd5-VP1 are 10~(10.62)个TCID_(50)/ml and 10~(11.87)个TCID_(50)/ml respectively. The recombinant viruses were passaged 5 times in 293A and the titer is still stable.. Expression of VP1 and multi-epitopes of FMDV were testified by PCR and western-blot, wetern-blot result indicated that expression products had specific antigenicity of FDMV.
4. VP1-2A gene of FMDV was and porcine Interleukin-2 gene was amplified from pMD18-VP1-2A and pMD18-poIL-2(pMD18-T contains porcine interleukin-2) respectively and cloned into pAdeno Vator-CMV5-IRES-GFP, named pA5VP1-2A-PoIL-2 and pA5-PoIL-2. Recombinant vectors were linearized by Pme I, and then linearized recombinant vectors and pAdeno VatorAEl/E3 co-transformed into E.coli BJ5183 competent cells by electrophoration. The homologous recombinant plasmids were selected and linearized by Pac I to expose the encapsidation signal. Linearized virus plasmids were transfected into 293A cells by Lipofectamine?2000, and recombinant viruses were named rAd5-VP1-2A-PoIL-2 and rAd5-PoIL-2. Western-blot indicated that rAd5-VP1-2A-PoIL-2 had specific antigenicity of FDMV and VP1-2A-PoIL-2 was cleaved by 2A with VP1-2A and PoIL-2. The lymphocyte proliferation test indicated that rPoIL-2 had biological activity.
5. Porcine IFN-a (PoIFN-a) gene was amplified from pMD18-poIFN-a, and cloned into pAdenoVator-CMV5-IRES-GFP vector containing VP1-2A gene, named pAd5VP1-2A-PoIFN-a, which was linearized by Pme I, and then linearized pAd5VP1-2A-PoIFN-a and pAdeno VatorAEl/E3 co-transformed into E.coli BJ5183 competent cells by electrophoration. The homologous recombinant plasmids pAd5VP1-2A- PoIFN-a was selected and Linearized by Pac I to expose the encapsidation signal. Linearized virus plasmids were transfected into 293A cells by Lipofectamine?2000, and recombinant viruses were named rAd5VP1-2A-PoIFN-a. Western-blot indicated that rAd5-VP1-2A-poIFN-a had specific antigenicity of FDMV and VP1-2A-PoIFN-a was cleaved by 2A with VP1-2A and PoIFN-a.. Recombinant virus was verified to be of high PoIFN-a activity by inhibiting the cyto-pathogenic effect, 10~5U/ml.
6. 6 weeks old female BALB/c mice were randomly separated into 14 groups, 12 mice per group, mice were inoculated intraperitoneal with recombinant viruses(rAd5VP1、rAd5EGS、rAd5poIL-2、rAd5poIFN-a、rAd5VP1-2A-poIFN-a and rAd5VP1-2A-poIL-2) three times at 2 weeks intervals, and with PBS and conventional inactivated vaccines as control. Level of IgG、IgG1、IgG2a、IL-4、IFN-γand proliferation T lymphocyte test were detected to evaluate humoral immune and cellular immune responses of recombinant viruses. The results indicated that rAd5VP1-2A-poIFN-a, rAd5VP1-2A-poIL-2 induced more stronger responses than inactivated vaccine done. The results indicated that cytokines (IFN-a and IL-2) enhanced immunity of recombinant virus. FMDV 2A separated the polyprotein into its single proteins and thus provide a maximal degree of freedom for cytokines activity, recombinant viruses showed VP1-2A-PoIL-2 and VP1-2A-PoIFN-a at a size of 25 kDa in Western blot analyses using an anti-FDMV antibody, revealing a proper cleavage of the fusion protein. ELISA test of antibody sub-type results indicated that recombinant viruses induced secretion both of IgG1 and IgG2a, partial to IgG1.The seem result elicited from cytokines ELISA test, secretion of both of Th1(γ-IFN) and Th2(IL-4) were induced by recombinant viruses, partial to Th2. This study demonstrates the VP1-2A-PoIL-2 (VP1-2A-PoIFN-a) fusion construct to be an efficient tool encoding two functions in one open reading frame. This promising candidate can be for instance in viral vectors vaccine studies. Thus provide valuable support for further development of FMD genetic engineering vaccines.
FMD弱毒疫苗和灭活疫苗等常规疫苗都具有良好的免疫原性，在预防和控制FMD的过程中发挥着重要作用，但由于病毒毒力返强、病毒灭活不彻底、活病毒逃逸疫苗加工厂等不安全因素。促使人们寻求一种更加安全有效的FMD疫苗。近年来，随着分子生物学技术的飞速发展，FMD基因工程疫苗等多种新型的疫苗都在不断的研究开发中，并取得了很好的成绩，但存在的问题是价格昂贵和动物保护试验不尽如人意。因此，研究者试图从多方面增强FMD疫苗的免疫效果，其中用细胞因子作为分子免疫佐剂，已引起众多研究者的关注。研究表明，许多细胞因子具有明显的免疫佐剂效应，可增强机体对抗原的反应性或增强抗原的免疫原性。细胞因子在体内缓慢而持久地释放，不会对机体产生毒性作用。具有佐剂效应的细胞因子有干扰素(IFN-α、IFN-β、IFN-γ)；淋巴因子(IL-2、IL-3、IL-4、IL-5、IL-10等)；单核因子(IL-1、IL-6、IL-8、IL-12等)及其它细胞因子。
本研究的目的是通过酵母表达系统和非复制型腺病毒载体系统表达口蹄疫病毒抗原基因及共表达抗原基因和免疫佐剂，研究免疫佐剂对重组蛋白和重组病毒的免疫增强作用，为口蹄疫基因工程疫苗的研究探索新的途径。研究主要从以下几个方面展开。
1．人工合成O型口蹄疫病毒VP1-2A基因，并克隆到pMDl8-T载体中，命名为pMD18-VP1-2A(上海Invitrogen公司完成)，以pMD18-VP1-2A为模板，设计一对引物，PCR扩增VP1基因，亚克隆到pET-32a(+)中，构建了表达载体pET-VP1，通过IPTG诱导表达，实现了融合蛋白VP1在大肠杆菌中的高效表达，表达融合蛋白为44kD左右，Western-blot试验表明，该重组蛋白具有免疫反应性。以纯化的重组VP1蛋白作为包被抗原，抗原最佳包被浓度确定为10.56μg／ml，能明显的区分口蹄疫病毒的阴阳性血清，建立了检测FMDV抗体的ELISA方法，为后期的研究打下基础。
2．人工合成O型口蹄疫病毒的多表位基因，并克隆到pMD18-T载体中，命名为pMD18-EG(上海Invitrogen公司完成)。另外，以含有人结核杆菌HSP70基因的质粒(pMD18-HSP70)为模板，设计引物PCR扩增HSP70基因。将目的基因克隆到酵母表达载体pPICZaA中，先后构建四个酵母表达载体pPICZaA-EG、pPICZaA-VP1、pPICZaA-EG-HSP70、pPICZaA-VP1-HSP70。通过电穿孔法将四个表达载体转化到酵母菌X-33中，用Zeocin~+平板筛选重组子，甲醇诱导表达，经SDS-PAGE电泳鉴定四个重组蛋白的大小分别约为23kD(rVP1)，20kD(rEG)，89kD(rEG-HSP70)，92kD(rVP1-HSP70)，免疫印迹分析后表明重组蛋白均具有免疫反应性。将四个重组蛋白以皮下接种的方式给小鼠进行3次免疫，同时设两组对照组小鼠，分别免疫PBS和常规灭活疫苗，然后通过测定IgG、IgGl、IgG2a、淋巴细胞增殖功能和IL-4、IFN-γ水平来衡量重组蛋白的免疫效果。结果表明重组蛋白既能诱导细胞免疫应答又能诱导体液免疫应答，rEG-HSP70产生的抗体与常规灭活苗相当，而细胞免疫水平从高到低依次为rEG-HSP70，rVP1-HSP70，灭活疫苗，rEG，rVP1。提示，HSP70作为分子佐剂在口蹄疫基因工程疫苗的研究中具有潜在的应用前景，为口蹄疫基因工程疫苗的研究提供一种新的思路。
3．重新设计引物扩增VPl和多表位基因，在多表位基因中加入通用型辅助性T淋巴细胞表位(PADRE)，并命名为EGS，分别将VP1和EGS基因克隆到腺病毒的穿梭载体pAdenoVator-CMV5-IRES-GFP中。得到的阳性穿梭质粒经PmeⅠ酶线性化后，利用电转化技术将线性化的质粒与腺病毒骨架载体pAdeno Vator△E1／E3共转化大肠杆菌BJ5183感受态细胞，使其在大肠杆菌中进行同源重组。将筛选到的重组病毒质：粒经PacⅠ酶线性化后暴露出包装信号，通过脂质体Lipofectamine ~(TM)2000转染293A细胞后得到重组病毒。利用报告基因GFP检测病毒滴度和感染效率，重组病毒rAd5-EGS和rAd5-VP1的滴度分别为10~(10.62)个TCID_(50)／ml和10~(11.87)个TCID_(50)／ml，重组病毒经过连续五代传代后效价稳定。通过PCR和western-blot证实FMDV V1l及表位基因得到成功的表达并有很好的免疫反应性。
4．分别以质粒pMD18-VP1-2A和以含有猪白细胞介素-2基因(PoIL-2)的质粒pMD18-PoIL-2为模板，PCR扩增VP1-2A和poIL-2基因，分别亚克隆到腺病毒的穿梭载体pAdenoVator-CMV5-IRES-GFP中。分别得到的阳性穿梭质粒pAd5polL-2和pAd5VP1-2A-PolL-2，经PmeⅠ酶线性化后，利用电转化技术将线性化的质粒与腺病毒骨架载体pAdenoVator△E1／E3共转化大肠杆菌BJ5183感受态细胞，使其在大肠杆菌中：进行同源重组。将筛选到的重组病毒质粒经PacⅠ酶线性化后暴露出包装信号，通过脂质体Lipofectamine ~(TM)2000转染293A细胞后得到重组病毒。Western-blot试验证实在FMDV 2A蛋白的介导下VP1-2A-PoIL-2裂解为VP1-2A和PoIL-2。同时，用淋巴细胞增殖试验分析单独表达PoIL-2和串联表达VP1-2A-poIL-2均具有刺激淋巴细胞增殖的生物活性。
5．以含有猪IFN-a基因的质粒pMD18-poIFN-a为模板，PCR扩增出poIFN-a基因，克隆到含有VP1-2A基因的腺病毒的穿梭载体pAdeno Vator-CMV5-IRES-GFP中。得到的阳性穿梭质粒pAd5VP1-2A-POIFN-a，经PmeⅠ酶线性化后，利用电穿孔法将其与腺病毒骨架载体pAdenoVator△E1／E3共转化大肠杆菌BJ5183感受态细胞，使其在大肠杆菌中进行同源重组。将筛选到的重组病毒质粒经PacⅠ酶线性化后暴露出包装信号，通过脂质体Lipofectamine ~(TM)2000转染293A细胞后得到重组病毒。Western-blot证实VP1-2A-PoIFN-a得到了表达，并在FMDV 2A蛋白的介导下VP1-2A-PoIFN-a裂解为VP1-2A和POIFN-a。细胞病变抑制法测定结果表明，重组猪a-干扰素具有较高抗病毒活性，10~5U／ml。
6．6周龄小鼠随机分为14组，每组12只。将6个重组病毒rAd5VP1、rAd5EGS、rAd5poIL-2、rAd5poIFN-a、rAd5VP1-2A-poIFN-a，rAd5VP1-2A-poIL-2分别以腹膜内接种的方式给小鼠进行3次免疫，同时设两组对照组小鼠，分别免疫PBS和常规灭活疫苗。然后通过测定IgG、IgG1、IgG2a、淋巴细胞增殖功能和IL-4、IFN-γ水平来衡量重组病毒的免疫效果。结果表明重组病毒既能诱导细胞免疫应答又能诱导体液免疫应答，rAd5VP1-2A-poIFN-a，rAd5VP1-2A-poIL-2免疫组的效果更优于其它免疫组，证实细胞因子发挥了明显的免疫佐剂效应。也进一步证实我们选用口蹄疫病毒2A蛋白介导细胞因子表达是正确的，因为只有2A发挥了有效的裂解作用，才能避免细胞因子在其氨基端融合其他蛋白而使构象发生改变，构象的改变可能会使它的功能和活性受到影响。抗体亚型测定结果显示，重组病毒既能诱导IgG1的分泌又能诱导IgG2a的分泌，但以IgG1为主。同时细胞因子ELISA试验结果进一步表明重组病毒主要刺激Th2分化(IL-4)，刺激Th1(γ-IFN)的分化的能力相对弱些。
以上实验证明，选择口蹄疫病毒2A蛋白酶介导口蹄疫病毒抗原基因与免疫佐剂在非复制型腺病毒载体表达系统中进行串联表达的设计思路是合理的，为口蹄疫基因工程疫苗的研究提供新的思路和见解。
Foot-and-mouth disease (FMD) was caused by FMDV, is a highly contagious, acute vesicular disease of cloven-hoofed animals, and is responsible for large economic losses, both as a direct result of the disease, and because of the necessary restrictions imposed on animal products and trade for disease control. Many researchers in the world pay attention to prevent and control this disease.
Although both of attenuated FMD vaccine and inactivated vaccine are effective, major problems were encountered such as unpredictable virulence in the field, high-containment vaccine production facilities, carried a slight risk of residual contamination of inactivated vaccines with live virus. Its use would most probably complicate the discrimination of naturally infected and vaccinated animals. Several novel approaches to vaccine development are emerging, and these may enjoy significant advantages over conventional vaccines. However, as yet they remain too costly for general veterinary use, and their immunogenicity is often limited. One way to remove this shortcoming is to improve the adjuvants used in the formulation of the vaccine. In general, there are some potent adjuvants, such as interferon(IFN-a、IFN-β、IFN-γ); lymph cytokines(IL-2、IL-3、IL-4、IL-5、IL-10); monocytines(IL-1、IL-6、IL-8、IL-12) and other cytokines.
In this study, the antigen of FMDV and some adjuvants (HSP70, PoIL-2, PoIFN-a) were co-expressed in methylotrophic yeast expression system and adenovirus vector expression system respectively. The affection of adjuvants on FMDV recombinant gene-engineering vaccine in mice was detected. This will provide novel ways for study of foot-and-mouth newly vaccine. All studies were listed as below:
1. VP1-2A gene of FMDV type O was synthesized and cloned into pMD18-T, named pMD18-VP1-2A (It had been done by Shanghai Invitrogen company) . VP1 gene was amplified from pMD18-VP1-2A and subcloned to pET-32a(+), named pET-VP1, recombinant VP1 was expressed in E.coli induced with IPTG. Recombinant protein was testified by SDS-PAGE, and which was expressed successfully and relative molecular mass was about 44kD. Western-blot result indicated that the recombinant protein had specific immunogenic characteristic against antibody of FDMV. ELISA test indicated that 10.56μg/ml of purified recombinant VP1 protein was coated as antigen can distinguish positive serum and negative serum of FMDV. This study was the basic for further study.
2. Multi-epitopes genes of 0 type foot-and-mouth diseases virus was synthesized and cloned into pMD18-T and named pMD18-EG (It had been done by Shanghai Invitrogen company). M.tuberculosis HSP70 gene was amplified from pMD18-HSP70. VP1 gene, EG gene and HSP70 gene were cloned into yeast expression vector pPICZaA. Four recombinant vectors were constructed and named pPICZaA-EG、pPICZaA-VP1、pPICZaA-EG-HSP70、pPICZaA-VP1-HSP70 respectively. Recombinant vector were transformed into methylotrophic yeast Pichia pastoris X-33 by electrophoration. The recombinant transformants were selected by Zeocin and induced by the addition of methanol every 24 h. The result of SDS-PAGE indicated that the recombinant proteins were successfully expressed in methylotrophic yeast Pichia pastoris and relative molecular mass were about 23kD(rVP1), 20kD(rEG), 89kD(rEG-HSP70), 92kD(rVP1-HSP70). Western blotting indicated that four recombinant proteins had specific antigenicity of FDMV. Mice were inoculated transcutaneous three times at a two-week interval with fusion protein, PBS and conventional inactivated vaccines. Level of IgG、IgG1、IgG2a、IL-4、IFN-γand proliferation T lymphocyte test were detected to evaluate humoral immune and cellular immune responses. The results indicated that fusion protein could elicit specific humoral immune and cellular immune responses. Compared with conventional inactivated vaccines, fusion protein elicited close to FMDV antibody level. Cellular immune responses in turn is rEG-HSP70, rVP1-HSP70, inactivated vaccine, rEG, rVP1, which suggest that HSP70 as molecular adjuvant can improve the immunogenicity of FMDV recombinant vaccine, thus provide valuable support for further development of FMDV genetic engineering vaccines.
3. VP1 gene and multi-epitopes gene were synthesized and cloned into pAdeno Vator-CMV5-IRES-GFP, named pA5-EGS and pA5-VP1 respectively. pA5-EGS and pA5-VP1 were Linearized by Pme I, and then linearized vector and pAdeno VatorΔE1/E3 co-transformed into E.coli BJ5183 competent cells by electrophoration. The homologous recombinant plasmids pAd5-EGS and pAd5-VP1 were selected and Linearized by Pac I to expose the encapsidation signal. Linearized virus plasmids were transfected into 293A cells by Lipofectamine ~(TM)2000, and recombinant viruses were named rAd5-EGS and rAd5-VP1. Infection titer and rate were evaluated through monitoring green fluorescent protein (GFP) expression. The filter of rAd5-EGS and rAd5-VP1 are 10~(10.62)个TCID_(50)/ml and 10~(11.87)个TCID_(50)/ml respectively. The recombinant viruses were passaged 5 times in 293A and the titer is still stable.. Expression of VP1 and multi-epitopes of FMDV were testified by PCR and western-blot, wetern-blot result indicated that expression products had specific antigenicity of FDMV.
4. VP1-2A gene of FMDV was and porcine Interleukin-2 gene was amplified from pMD18-VP1-2A and pMD18-poIL-2(pMD18-T contains porcine interleukin-2) respectively and cloned into pAdeno Vator-CMV5-IRES-GFP, named pA5VP1-2A-PoIL-2 and pA5-PoIL-2. Recombinant vectors were linearized by Pme I, and then linearized recombinant vectors and pAdeno VatorAEl/E3 co-transformed into E.coli BJ5183 competent cells by electrophoration. The homologous recombinant plasmids were selected and linearized by Pac I to expose the encapsidation signal. Linearized virus plasmids were transfected into 293A cells by Lipofectamine?2000, and recombinant viruses were named rAd5-VP1-2A-PoIL-2 and rAd5-PoIL-2. Western-blot indicated that rAd5-VP1-2A-PoIL-2 had specific antigenicity of FDMV and VP1-2A-PoIL-2 was cleaved by 2A with VP1-2A and PoIL-2. The lymphocyte proliferation test indicated that rPoIL-2 had biological activity.
5. Porcine IFN-a (PoIFN-a) gene was amplified from pMD18-poIFN-a, and cloned into pAdenoVator-CMV5-IRES-GFP vector containing VP1-2A gene, named pAd5VP1-2A-PoIFN-a, which was linearized by Pme I, and then linearized pAd5VP1-2A-PoIFN-a and pAdeno VatorAEl/E3 co-transformed into E.coli BJ5183 competent cells by electrophoration. The homologous recombinant plasmids pAd5VP1-2A- PoIFN-a was selected and Linearized by Pac I to expose the encapsidation signal. Linearized virus plasmids were transfected into 293A cells by Lipofectamine?2000, and recombinant viruses were named rAd5VP1-2A-PoIFN-a. Western-blot indicated that rAd5-VP1-2A-poIFN-a had specific antigenicity of FDMV and VP1-2A-PoIFN-a was cleaved by 2A with VP1-2A and PoIFN-a.. Recombinant virus was verified to be of high PoIFN-a activity by inhibiting the cyto-pathogenic effect, 10~5U/ml.
6. 6 weeks old female BALB/c mice were randomly separated into 14 groups, 12 mice per group, mice were inoculated intraperitoneal with recombinant viruses(rAd5VP1、rAd5EGS、rAd5poIL-2、rAd5poIFN-a、rAd5VP1-2A-poIFN-a and rAd5VP1-2A-poIL-2) three times at 2 weeks intervals, and with PBS and conventional inactivated vaccines as control. Level of IgG、IgG1、IgG2a、IL-4、IFN-γand proliferation T lymphocyte test were detected to evaluate humoral immune and cellular immune responses of recombinant viruses. The results indicated that rAd5VP1-2A-poIFN-a, rAd5VP1-2A-poIL-2 induced more stronger responses than inactivated vaccine done. The results indicated that cytokines (IFN-a and IL-2) enhanced immunity of recombinant virus. FMDV 2A separated the polyprotein into its single proteins and thus provide a maximal degree of freedom for cytokines activity, recombinant viruses showed VP1-2A-PoIL-2 and VP1-2A-PoIFN-a at a size of 25 kDa in Western blot analyses using an anti-FDMV antibody, revealing a proper cleavage of the fusion protein. ELISA test of antibody sub-type results indicated that recombinant viruses induced secretion both of IgG1 and IgG2a, partial to IgG1.The seem result elicited from cytokines ELISA test, secretion of both of Th1(γ-IFN) and Th2(IL-4) were induced by recombinant viruses, partial to Th2. This study demonstrates the VP1-2A-PoIL-2 (VP1-2A-PoIFN-a) fusion construct to be an efficient tool encoding two functions in one open reading frame. This promising candidate can be for instance in viral vectors vaccine studies. Thus provide valuable support for further development of FMD genetic engineering vaccines.
引文
[1] 陈溥言主编．兽医传染病学[M]．第五版，72-74
[2] Esteban Domingo, Eric Baranowski, Cristina Escarmi's Francisco Sobrino. Foot-and-mouth disease virus[J]. Microbiology & Infectious Diseases, 2002,25:297-308
[3] 江鹏斐，赵启祖，谢庆阁．口蹄疫研究进展[J]．中国农业科学，1999，32(6)：93～100
[4] 柳纪省．口蹄疫研究进展[J]．中国兽医科技．1999，29(3)：17-22
[5] 刘庆军，张永光．口蹄疫病毒基因组结构及其功能[J]．动物医学进展，2005，26(5)：1-5
[6] Martinez Salas E. Internal ribosome entry site biology and it s use in expression vector [J].Curr Opin Biotechnol, 1999, 10:458-464
[7] 卢曾军，刘在新．口蹄疫病毒研究概况[J]．中国兽医科技．2003,33(2)：69-74
[8] Stassinopoulos I A, Belsham GJ. A novel protein-RNA binding assay: functional interactions of the foot-and-mouth disease virus internal ribosome entry site with cellular proteins[J].RNA, 2001, 7(1):114-122
[9] Ohlmann T, Jackson R J. The properties of chimeric picornavirus IRESes show that internal translation initiation sites is influenced by the identity of the IRES and not just the context of the AUG codon[J]. RNA,1999,5(6):764-778
[10] Lopez de Quinto S, Lafuente E, Martinez-Salas E. IRES interaction wit h t ranslation initiation factors: functional characterization of novel RNA contact s wit h elF3, elF4B, and eIF4GⅡ[J]. RNA,2001,7(9):1213-1226
[11] Niepmann M. Effect s of potassium and chloride on ribosome association with the RNA of foot-and-mouth disease virus [J].Virus Res,2003,93(1):71-78
[12] Haydon D T, Samuel A R, Knowles N J. The generation and persistence of genetic variation in foot-and-mouth disease virus[J]. Prev Vet Med,2001,51: 111-124
[13] Marquardt O, Freiberg B. Antigenic variation among foot-and-mouth disease virus type A field isolates of 1997-1999 from Iran[J].Vet Microbiol,2000,74(4):377-386
[14] Araujo J P J r, Montassier H J, Pinto A A.Extensive antigenic and genetic variation among foot-and-mouth disease type A viruses isolated f rom the 1994 and 1995 foci in Sao Paulo , Brazil[J]. Vet Microbiol,2002,84(12):15-27
[15] PRATHAPAM TU,ASIRAM, MUDIT TYAGI, et al. Antigenic Variation in Foot and Mouth Disease Virus Type Asia 1 Isolates Circulated During 1993-95 in India[J].Virus Genes 1997,15(3):247-253
[16] Fares M A, Mora A, Escarmis C, etal. Evidence for positife selection in the capsid protein-coding region of the foot-and-mouth disease virus (FMDV) subjected to experimental passage regimens[J]. Mol Biol Evol,2001,18:10-21
[17] Manoj Kumar R, Sanyal A, Tosh C, et al. Mutation in the 1D gene (VP1) of foot-and-mouth disease virus serotype Asia I during serial cytolytic infections in cell culture[J].Arch Virol,2003,148(9):1815-1825
[18] 沈小燕，丛国正，常惠芸，等．口蹄疫病毒的抗原变异与逃避免疫反应[J]．中国兽医科技，2004，34(12)：33-37
[19] Butchaiah G, Morgan D O. Neutralization antigenic sites on type Asia-1 Foot-and-mouth disease virus defined by monoclonal antibody-resistant variants[J]. Virus Res,1997,52 (2):183-194
[20] Marquardt O, Rahman M M,Freiberg B. Genetic and antigenic variance of Foot-and-mouth disease virus type Asia-l[J]. Arch Virol,2000,145:149-157
[21] Zhang H Y, Sun S H, Guo Y J, et al. Immune response in mice inoculated with plasmid DNAs containing multiple-epitopes of Foot-and-mout h disease virus[J]. Vaccine,2003,21 (32):4704-4707.
[22] Blanco E, Briones G M, Sanz-Parra A,et al. Identification of T-cell epitopes in nonstructural proteins of Foot-and-mouth disease virus[J]. J Virol,2001,75(7):3164-3174
[23] Zhang Q, Yang Y Q, Zhang Z Y, et al. Immunogenicity of a recombinant fusion protein of tandem repeat epitopes of Foot-and-mouth disease virus type Asia 1 for guinea pigs[J]. Acta Virol,2002,46(1):1-9
[24] Schneider Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis[J].J Gen Virol, 2000, 81:1413-1429
[25] Baxt B, Neff S, Rieder E,et al. Foot-and-mouth disease virus-receptor interactions: Role in pathogenesis and tissue culture adsorption. In: Molecular Biology of Picronaviruses [P]. 2002, 115-123
[26] Jackson T, King A M, Stuart D I. Structure and receptor binding[J]. Virus Res, 2003, 91:33-46
[27] Wolfgang Ernst, Theresa Schinko, Alexandra Spenger, et al. Improving baculovirus transduction of mammalian cells by surface display of a RGD-motif[J]. Journal of Biotechnology, 2006, 126:237-240
[28] Jackson T, Mould A P, Sheppard D, et al. Integrin alphavbetal is a receptor for foot-and-mouth disease virus[J]. J Virol, 2002,76:935-941
[29] Leippert M, Beck E, Weiland F, et al. Point mutations within the G-H loop of foot-and-mouth disease virus O1K affect virus attachment to target cells[J]. J Virol,1997,71:1046-1051
[30] Duque H, Baxt B. Foot-and-mout h disease virus receptors: comparison of bovine alpha (V) integrin utilization by type A and O viruses[J]. J Virol,2003,77:2500-2511
[31] 沈小燕，常惠芸，丛国正，等．口蹄疫病毒感染细胞的研究进展[J]．动物医学进展，2005，26(6)：1-5
[32] 程泽华．口蹄疫的流行及其病毒的细胞受体[J]．畜禽业，2003，7：9
[33] Michael N, Anke P, Karsten M, et al. Functional involvement of polypyrinmidine tract-binding protein in translation iniation complexes with the internal ribosome entry site of foot-and-mouth virus[J]. J Virology,1997,71:8330～8339
[34] Lopez de Quinto S, Martinez2Salas E. Interaction of the elF4G initiation factor with the aphthovirus IRES is essential for internal translation initiation in vivo[J]. RNA,2000,6:1380-1392
[35] Belsham GJ, J ackson R J. Translation initiation on picornavirus RNA[M]. Translational Control of Gene Expression, New York Cold Spring Harbor Laboratory Press, Cold Spring Harbor:,2000,869-900
[36] Mason P W, Bezborodovan S V, Henry T M. Identification and characterization of a cisacting replication element (cre) adjacent to the IRES of foot-and-mout h disease virus[J]. J Virol,2002, 76:9686-9694
[37] Tiley L, King A M, Belsham G J. The foot-and-mout h disease virus cis-acting replication element (cre) can be complemented in trans within infected cells [J]. J Virol,2003, 77:2243-2246
[38] Nugent C I, Johnson K L, Sarnow P, et al. Functional coupling between replication and packaging of poliovirus replicon RNA[J]. J Virol,1999,73:427-435
[39] Sasaki J, Taniguchi K. The 5-end sequence of t he genome of Aichi virus, a picornavirus, contains an element critical for viral RNA encapsidation[J]. J Virol,2003,77:3542-3548
[40] Domingo E, Escarmis C, Baranowski E, et al. Evolution of foot-and-mout h disease virus[J]. Virus Res,2003,91:47-63
[41] 张海峰，富相奎．口蹄疫的流行与防制[J]．黑龙江农业科学2006，(1)：59～60
[42] 江鹏斐．口蹄疫研究进展[J]．中国农业科学，2000，(6)：93-100．
[43] 龚团莲，孙立杰，毛景东，等．口蹄疫研究概述[J]．内蒙古民族大学学报，2001，16(2)：393-396．
[44] Zinna, Kettlewell Hill. Foot and mouth disease[J]. Research in Veterinary Science, 2002, 73, 195-199
[45] Marvin J., Grubman, Barry Baxt. Foot-and-Mouth Disease[J].CLINICAL MICROBIOLOGY REVIEWS, 2004, 17(2):465-493
[46] 鲜思美，周碧君，文明，等．口蹄疫实验诊断技术研究进展[J]．山地农业生物学报，2006，25(1)：77～81
[47] 卢永干．用口蹄疫非结构蛋白鉴别康复动物与注射疫苗动物的研究及应用[J]．中国兽医科技，2000，30(10)：18-20
[48] 何永强，杜青云，盛祖恬，等．猪口蹄疫和水泡病病毒免疫鉴别诊断方法的比较[J]．中国预防兽医学报，1999，21(3)：228-230
[49] 朱彩珠，张强，常惠芸，等．NSP-ELISA鉴别口蹄疫病毒感染与免疫[J]．中国兽医科技，2004，33(8)：3-6
[50] M ezencio J M S, Babcock G D,M eyer R F, et al. Differentiating foot-and-mouth disease virus-infected from vaccinated animals with baculovirus-expressed specific proteins[J]. Vet Quart, 1998, 20(2):11-13
[51] Blanca Robiolo, Cristina Seki, Norberto Fondevilla, et al. Analysis of the immune response to FMDV structural and non-structural proteins in cattle in Argentina by the combined use of liquid phase and 3ABC-ELISA tests[J]. Vaccine, 2006,24:997-1008
[52] R.M. Armstrong, S.J. Cox, N. Aggarwal, et al. Detection of antibody to the foot-and-mouth disease virus (FMDV) non-structural polyprotein 3ABC in sheep by ELISA[J]. Journal of Virological Methods, 2005, 125:153-163
[53] Maria Gabriela Lopez, Andrea Peraltaa, Analia Berinsteina, et al. High-level expression of recombinant 3AB1 non-structural protein from FMDV in insect larvae[J]. Journal of Virological Methods, 2005, 124:221-224
[54] S. Parida, S.J. Cox, S.M. Reid, et al. The application of new techniques to the improved detection of persistently infected cattle after vaccination and contact exposure to foot-and-mouth disease[J]. Vaccine, 2005, 23(44): 5186-5195
[55] Jae Ku Oem, Byung Sik Chang, Hoo Don Joo. Development of an epitope-blocking-enzyme-linked immunosorbent assay to differentiate between animals infected with and vaccinated against foot-and-mouth disease virus [J]. Journal of Virological Methods, 2007,142:174-181
[56] B. Freiberg, B. Ho'" hlich, B. Haas, et al. Type-independentdetection of foot-and-mouth disease virus by monoclonal antibodies that bind to amino-terminal residues of capsid protein VP2[J]. Journal of Virological Methods, 2001, 92:199-205
[57] Ming Yang, Alfonso Clavijo, Mingyi Li, et al. Identification of a major antibody binding epitope in the non-structural protein 3D of foot-and-mouth disease virus in cattle and the development of a monoclonal antibody with diagnostic applications[J]. Journal of Immunological Methods, 2007, 321:174-181
[58] 蒋正军，尹燕博，龚振华，等．运用RT-PCR一步法和Nested-PCR法快速检测FMDV的研究[J]．中国动物检疫，1997，14，(2)：3-4
[59] 王伊琴，胡烈山，银泉，等．应用RT-PCR检测灭活疫苗中口蹄疫病毒(核酸)[J]．检验检疫科学，2003，13，(4)：48-49
[60] 朱彩珠，卢永干，邱孝高，等．应用反转录一聚合酶链反应检测口蹄疫病毒[J]．病毒学报，1998，14(3)：272-277
[61] 娄高明，杜伟贤，杨傲冰，等．应用RT-PCR技术检测动物组织中的口蹄疫病毒[J]．微生物学报，2002，29(4)：9-13
[62] 罗长保，鱼海琼，林志雄，等．应用荧光RT-PCR技术检测口蹄疫病毒[J]．中国兽医杂志，2003，39(12)：31
[63] Palani Giridharan, Divakar Hemadri, Chakradhar Tosh, et al. Development and evaluation of a multiplex PCR for differentiation of foot-and-mouth disease virus strains native to India[J]. Journal of Virological Methods, 2005, 126:1-11
[64] Jajati Keshari Mohapatra, Aniket Sanyal, Divakar Hemadri, et al. Development and comparison of genome detection assays for the diagnosis of foot-and-mouth disease suspected clinical samples[J]. Journal of Virological Methods, 2006, 137:14-20
[65] S. M. Reid, N. P. Ferris, G. H. Hutchings, et al. Diagnosis of foot-and-mouth disease by RT-PCR:use of phylogenetic data to evaluate primers for the typing of viral RNA in clinical samples[J]. Arch Virol, 2001, 146:2421-2434
[66] Thomas Bruun Rasmussen, A° se Uttenthal, Monserrat Agn"ero. Detection of three porcine vesicular viruses using multiplex real-time primer-probe energy transfer[J]. Journal of Virological Methods, 2006, 134:176-182
[67] 吕景福，陈橙，李邦佑，等．牲畜口蹄疫的综合防制[J]．湖北畜牧兽医，2005，2：37-38
[68] 田增义．口蹄疫的防制[J]．中国动物保健，2005，7：7-14
[1] 蒋文俊，李华春，李乐，等．口蹄疫疫苗研究进展[J]．畜牧与兽医，2004，36(5)：42-43
[2] 徐全武，申涛，马雪峰．口蹄疫疫苗研究进展[J]．新疆畜牧业，2003，3：47-48
[3] 王永录，张永光，方玉珍，等．牛O-A型口蹄疫双价灭活苗研究：效力试验和最小免疫剂量试验[J]．中国兽医科技，1999，29(9)：3-4
[4] V. Balamurugan, R. Renji, G. Venkatesh, et al. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant P1 polyprotein expressed in Pichia pastoris[J].Arch Virol, 2005, 150:967-979
[5] Jeng-Hwan Wang, Chi-Ming Liang, Jei-Ming Peng, et al. Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus[J].Vaccine, 2003,21:3721-3729
[6] Taboga O, Tami C, Carrillo E. et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants[J]. Virol, 1997, 71(4):2606-2614
[7] Judit Villen, Eliandre de Oliveira, Jose Ignacio Nunez, et al. Towards a multi-site synthetic vaccine to foot-and-mouth disease: addition of discontinuous site peptide mimic increases the neutralization response in immunized animals[J].Vaccine, 2004,22:3523-3529
[8] Eliandre de Oliveira, Miguel Angel Jimenez-Clavero, et al. Analysis of the immune response against mixotope peptide libraries from a main antigenic site of foot-and-mouth disease virus[J].Vaccine,2005,23:2647-2657
[9] Chinsangaram J, Beard C, Mason P W, et al. Antibody response in mice inoculated with DNA expressing Foot-and-mouth disease virus capsid proteins[J].J. Virol, 1998, 72 (5):4454-4457
[10] Jian-Zhong YI, Ming-Qiu LIU, Cai-Zhu ZHU, et al. Recombinant Bivalent Vaccine against Foot-and-Mouth Disease Virus Serotype O/A Infection in Guinea Pig[J]. Acta Biochemica et Biophysica Sinica 2004, 36(9): 589-596
[11] Leticia Cedillo-Barron, Mildred Foster-Cuevas, Audra Cook,Benito Gutiérrez-Castafieda, et al. Parkhouse. Immunogenicity of plasmids encoding T and B cell epitopes of foot-and-mouth disease virus (FMDV) in swine[J]. Vaccine, 2003, 21:4261-4269
[12] Belen Borrego, Paloma Fernandez-Pacheco, Llilianne Ganges, et al. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses[J]. Vaccine, 2006, 24(18):3889-3899
[13] V. Niborski, Y. Li, F. Brennan, et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV[J]. Vaccine, 2006, 24:7204-7213
[14] Fang Wang, Xiao-Wen He, Lei Jiang, et al. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice[J]. Vaccine, 2006, 24:2017-2026
[15] Yanmin Li, Neeraj Aggarwal, Haru-H. Takamatsu, et al. Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O[J]. Vaccine, 2006, 24:4602-4606
[16] Benvenisti L, Rogel A, Kuznetzova L, et al. Gene gun-mediate DNA vaccination against Foot-and-mouth disease virus[J].Vaccine, 2001, 19:3885-3895
[17] Wong H T, Cheng S C S, Chan E W C, et al. Plasmids encoding Foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J].Virology, 2000, 278:27-35
[18] 李光金，严维耀，徐泉兴，等．以猪IgG重链恒定区为抗原载体的抗口蹄疫病毒DNA疫苗的研制[J]．生物工程学报，2001，17(3)：322-324
[19] OSCAR TABOGA, CECILIA TAMI, ELISA CARRILLO, et al. A Large-Scale Evaluation of Peptide Vaccines against Foot-and-Mouth Disease:Lack of Solid Protection in Cattle and Isolation of Escape Mutants[J].JOURNAL OF VIROLOGY, 1997, Apr., 2606-2614
[20] 李光金，李颖杰，严维耀，等．CpG DNA增强口蹄疫病毒DN疫苗诱发豚鼠产生的免疫应答[J]．科学通报，2001，46(3)：477-480
[21] Wong H T, Cheng S C S, Sin F W Y, et al. A DNA vaccine against Foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J].Vaccine, 2002, 20:2641-2647
[22] Luis L. Rodriguez, Jose Barrera, Ed Kramer, et al. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge[J]. Vaccine,2003, 21:3751-3756
[23] Yun-Gang Li, Fu-Lin Tian, Feng-Shan Gao, et al. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus[J].Vaccine, 2007, 25(5):902-911
[24] Liang Chen, HanJuan Shao. Extract from Agaricus blazei Murill can enhance immune responses elicited by DNA vaccine against foot-and-mouth disease[J].Veterinary Immunology and Immunopathology, 2006,109:177-182
[25] Anne-Sophie Beignon, Fred Brown, Pierre Eftekhari, et al. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralizing anti-FMDV antibody responses[J]. Veterinary Immunology and Immunopathology, 2005,104:273-280
[26] Shieh J J ,Liang CM , Chen C Y, et al. Enhancement of the immunity to Foot-and-mouth disease virus by DNA priming and protein boosting immunization[J]. Vaccine, 2001,19: 4002-4010
[27] Huali Jin, Youmin Kang, Guoxing Zheng, et al. Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines[J]. Virology, 2005,337:183 -191
[28] Chan E W C, Wong H T, Cheng S C S, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine [J].Vaccine, 2001,19:538-546
[29] Guangjin Lia, Weizao Chena, Weiyao Yana, et al. Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or β-galactosidase as a carrier of immunogenic epitopes[J]. Virology, 2004,328:274-281
[30] Sreerupa Challa, Roger Barrette, Debra Rood, et al. Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus.[J]. Vaccine, 2007,25:3328-3337
[31] Baranowski E, Ruiz-jarabo C M, Sevilla N, et al. Cell Recognition by Foot-and-mouth disease uirus That lacks the RGD Integrin-Binding Motif: Flexibility in Aphthovirus Receptor Usage[J]. J Virol, 1999,73:2739-2744
[32] Ping Qian, Xiang-Min Li, Mei-Lin Jin, et al. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine[J]. Vaccine, 2004, 22:2129-2136
[33] Sanz-Parra A, Uazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor poly peptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80:671-679
[34] Min Zheng, Ningyi Jin, Hongyong Zhang, et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease viras[J]. Journal of Virological Methods, 2006,136:230-237
[35] Berinstein A, Tami C, Taboga O, et al. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus[J]. Vaccine, 2000,18:2231-2238
[36] G. A. Mayr, Jarasvech Chinsangaram, Marvin J. Grubman Development of Replication-Defective Adenovirus Serotype 5 Containing the Capsid and 3C Protease Coding Regions of Foot-and-Mouth Disease Virus as a Vaccine Candidate[J]. Virology, 1999, 263:496-506
[37] G. A. Mayr, O'Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus- FMDV constructs[J]. Vaccine, 2001,19:2152-2162
[38] Mauro P. Moraes, Jarasvech Chinsangaram, Mario C.S. Brum, et al. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine[J]. Vaccine, 2003,22:268-279
[39] Juan M. Pacheco, Mario C.S. Brum, Mauro P. Moraes, et al. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vector FMDV subunit vaccine[J]. Virology, 2005, 337 205-209
[40] Sonia de Avila Botton, Mario C.S. Brum, Elida Bautista, et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha.[J]. Vaccine, 2006, 24:3446-3456
[41] N. Gomez, C.Carrillo, J. Salinas, et al. Expression of Immunogenic Glycoprotein S Polypeptides from Transmissible Gastrenteritis Coronavirus in Transgenic Plants[J].Virology 1998, 249(2):352-358
[42] Dong-Mei He, Kai-Xian Qian, Gui-Fang Shen, et al . Stable expression of foot-and-mouth disease virus protein VP1 fused with cholera toxin B subunit in the potato (Solarium tuberosum) [J]. Colloids and Surfaces B: Biointerfaces, 2007,55:159-163
[43] Wigdorovitz A.,D.M.Perez Filgueira, C. Carrillo, et al. Protection of mice against challenge with foot and mouth disease with foliar exacts from plants infected with recombinant tobacco mosaic virus expressing th FMDV structural protein VP1[J].Virology, 1999,264:85-91
[44] Lubin Jiang, Qiaoli Li, Mangmang Li, et al. A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco[J]. Vaccine, 2006, 24:109-115
[45] Carrillo C, Wgdorovitz A, Oliveros C, et al. Protective immune response to foot and mouth disease virus with VP1 expressed in transgenic plants[J].J Virol,1998,72:1688-1690
[46] C. Carrillo, A. Wigdorovitz, K. Trono, et al. Induction of a virus specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants[J]. Viral Immunol, 2001,14:49-57
[47] Wigdorovitz A, Carrillo C, Dus Santos MJ,et al.Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein[J]. Virol, 1999, 255(2):347-353
[48] Mar'ia J. Dus Santos, Consuelo Carrillo, Fernando Ardila, et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen[J]. Vaccine, 2005, 23:1838-1843
[49]余云舟,王罡,金宁一,等．口蹄疫病毒结构蛋白P1基因转化玉米的初步研究[J]．玉米科学,2004,12(3)：22—25
[50] 李昌，金宁一，王罡，等．口蹄疫病毒P1全长基因表达载体的构建及对马铃薯的转化[J]．吉林农业大学学报，2004，26(5)：507-510
[51] 李文建，沈明山，李春江，等．口蹄疫抗原决定簇融合基因转化胡萝卜的研究[J]．厦门大学学报(自然科学版)，2005，44：154-157
[52] 倪志华，张红心，王鸣刚，等．口蹄疫抗原决定簇融合基因转化水稻的研究[J]．厦门大学学报(自然科学版)，2005，44：158-1
[1] 卢曾军，刘在新．口蹄疫病毒研究概况[J]．中国兽医科技，2003，33(2)：69-74
[2] Esteban Domingo, Eric Baranowski, Cristina Escarmi's Francisco Sobrino. Foot-and-mouth disease virus[J]. Comparative Immunology, Microbiology & Infectious Diseases, 2002, 25:297-308
[3] Zinna, Kettlewell Hill. Foot and mouth disease[J]. Research in Veterinary Science 2002, 73:195-199
[4] Marvin J. Grubman, Barry Baxt. Foot-and-Mouth Disease[J].CLINICAL MICROBIOLOGY REVIEWS, 2004, 17(2):465-493
[5] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆试验指南，第二版，1999：49-52
[6] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆试验指南，第二版，1999：19-21
[7] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆实验指南，第二版，1999：845-888
[1] 江鹏斐，赵启祖，谢庆阁．口蹄疫研究进展[J]．中国农业科学，1999，32(6)：93-100
[2] Hong-Ying Zhang,Shu-Han Sun,Ying-Jun Guo,et al. Immune response in mice inoculated with plasmid DNAs containing multiple-epitopes of foot-and-mouth disease virus[J]Vaccine 2003,21:470-4707
[3] Wong HT, Cheng SCS,Chan EWC,et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J].Virology,2000,278:27～35
[4] 欧阳立明，张惠展，张嗣同．巴斯德毕赤酵母的基因表达系统研究进展[J]．生物化学与生物物理进展2000，27(2)：151-154
[5] 彭毅，杨希才，康良仪．影响甲醇酵母外源蛋白表达的因素[J]．生物技术通报，2000，4：33-36
[6] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆试验指南[M]，第二版，1999，24-28
[7] 剧海，梁东春，郭刚，等．用于PCR实验的毕赤酵母基因组DNA制备方法的比较[J]．天津医药．2003，31(5)：270-272
[8] Beard C,Ward G,Rieder E,et al. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine [J].J.Biotechnol,1999,73(223):243—249
[9] ASEA A,KRAEFT SK, JONES EAK, et aI.HSP70 stimulate cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine[J].Nature Medicine,2000,4:435-436
[10] Udono H,Yamano T,Kawabata Yet al. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70[J].Inter Immunol, 2001, 13(10): 1233-1242
[11] Planelles L, Thomas MC, Alonso C, et al. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMPll protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection[J]. Infect Immun 2001;69:6558-6563
[12] 杨晟，黄鹤，章如安．重组人血清蛋自在Pichia pastoris中分泌表达影响因素的研究[J]生物工程学报2000，16(6)：675-678
[13] EasySelect Pichia Expression Kit, Catalog no.K1740-01, Invitrogen
[1] 卢曾军，刘在新．口蹄疫病毒研究概况[J]．中国兽医科技，2003，33(2)：69-74
[2] Tami C, Farber M, Palma E L, et al. Presentation of antigenic sites from foot-and-mouth disease virus on the surface of baculovirus and in the membrane of infected cells.[J].Arch Virol, 2000, 145(9): 1815-1828
[3] Mayr GA, O'Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs[J].Vaccine, 2001, 19(15-16):2152-2162
[4] Cox S J, Barnett P V, Dani P, et al. Emergency vaccination of sheep against foot and mouth disease: Protection against disease and reduction in contact transmission[J]. Vaccine, 1999, 17(15-16):1858-1868
[5] Wigdorovitz A, Perez Filgueira D M. Protection of mice against challenge with foot and mouth disease virus(FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1[.J]Virology, 1999, 264(1): 85-91
[6] Berinstein A, Tami C, Taboga O, et al. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus[J]. Vaccine, 2000, 18(21): 2231-2238
[7] Grubman M J, Baxt B. Foot-and-Mouth Disease[J]. Clinical Microbiol, 2004, 17:465-493.
[8] 李光金，李颖杰，严维耀，等．CpG DNA增强口蹄疫病毒DNA疫苗诱发豚鼠产生的免疫应答[J]．科学通报，2001，46(3)：477-480
[9] Wong H T, Cheng S C S, Sin F W Y, et al. A DNA vaccine against Foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J]. Vaccine, 2002, 20:2641-2647
[10] ASEA A,KRAEFF SK,JONES EAK, et al.HSP70 stimulate cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine[J].Nature Medicine,2000,4:435-436
[1] Wong HT, Cheng SC, Chan EW, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J]. Virology, 2000, 278(1):27-35
[2] Hohlich B J, Wiesmuller KH, Haas B, et al. Induction of an antigenspecific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B-cell epitopes[J].J Gen Virol 2003,84(12):3315-3324
[3] Sanz-Parra A, Vazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80(P3):671-679
[4] Sanz-Parra A, Jimenez-Clavero M A, Garcia-Briones M M, et al. Recombinant viruses expressing the foot-andmouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology, 1999, 259(1):129-134
[5] Garcia-Briones M M, Blanco E, Chiva C, et al. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D[J]. Virology, 2004, 322(2):264-275
[6] Ping Qian, Xiang-Min Li, Mei-Lin Jin, et al. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine[J]. Vaccine 22 (2004) 2129-2136
[7] Sanz- Parra A, Uazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor poly peptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80:671-679
[8] A lexander J, F ikes J, Hoffman S, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development [J]. Immuno 1 Res, 1998, 18:79-92
[9] Crouzet J, Naudin L, Orsinic C, et al. Recombinational construction in Escherichia coli of infections adenovirual genomes[J].Proc Natl Acad Sci USA, 1997, 94:14
[10] T C He, S Zhou, L T Costa, et al. A simplified system for generating recombinant adenovirnses[J]. Proc Nail Acad Sci USA, 1998, 95:2509-2514
[1] Gaff en SL, Liu KD. Overview of interleukin-2 function, production and clinical applications[J]. Cytokine, 2004, 7, 28 (3):109-123
[2] At kins MB, Kunkel L, Sznol M, et al. High-dose recombinant intedeukin-2 therapy in patients with metastatic melanoma: long term survival update[J]. Cancer J Sci Am, 2000, 6 (Suppl1): 11-14
[3] Hyung Joon Cha, Hwa Sung Shin, Hye Jung Lim, et al. Comparative production of human interleukin-2 fused with green fluorescent protein in several recombinant expression systems[J]. Biochemical Engineering Journal, 2005, 24:225-233
[4] James P. McGettigan, Martin L. Koser, Philip M. McKenna,et al. Enhanced humoral HIV-l-specifc immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2[J]. Virology, 2006, 344:363-377
[5] Yann Pellequer, Michel Ollivon, Gillian Barratt. Formulation of liposomes associated with recombinant intedeukin-2: effect on interleukin-2 activity[J]. Biomedicine & Pharmacotherapy, 2004, 58:162-167
[6] Rashika E1 Ridi, Rabab Salem, Areal Wagih. Influence of interleukin-2 and interferon-gamma in murine Schistosomiasis[J]. Cytokine, 32006, 3:281-288
[7] L.V. Cherenova, D.Y. Logunov, E.V. Shashkova. Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo[J]. Virus Research, 2004, 100:257-261
[8] John H. Wyckoff Ⅲ, Jeri L. Howland, Catherine M. O'Connell Scott, et al. Recombinant bovine interleukin-2 enhances immunity and protection induced by Brucella abortus vaccines in cattle[J]. Veterinary Microbiology, 2005, 111:77-87
[9] Silja A° vall-Ja"a"skela"inen, Airi Palva. Secretion of biologically active porcine interleukin-2 by Lactococcus lactis[J]. Veterinary Microbiology, 12006, 15:278-283
[10] Ho-Tsun Wong, Samuel Chak-Sum Cheng, et al. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J]. Vaccine, 2002, 20:2641-2647
[11] Yan Lin, He Qigai, Yu Xiaolan, et al. The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs[J]. Vaccine, 2005, 23:4436-4441
[12] Shashi A. Gujar, Tomasz I. Michalak .Characterization of bioactive recombinant woodchuck interleukin-2 amplified by RLM-RACE and produced in eukaryotic expression system[J]. Veterinary Immunology and Immunopathology, 2006,112:183-198
[13] Ji-Yong Zhou, Jin-Yong Wang, Ji-Gang Chen, et al Cloning, in vitro expression and bioactivity of duck interleukin-2[J]. Molecular Immunology, 2005,42:589-598
[14] Maria C. Denis, Brigitte T. Huber. Native and recombinant interleukin-2, two functionally distinct molecules[J]. Molecular Immunology, 2003, 40:279-286
[15] KimJ J ,Trivedi N N ,Nottingham L K et al . Modulation of amplitude and direction of in vivo immune responses by co- administration of cytokine gene expression cassettes with DNA immunogens[J]. Eur J Immunol,1998, 28:1089-1093
[16] Chow Y H , Huang W L ,Chi W K et al. Improvement of hepatitis B virus DNA vaccines by plasmids co-expressing hepatitis B surface antigen and interleukine-2[J]. J Virol,1997, (1):169-178
[17] Chow Y H ,Chiang B L ,Lee YL et al. Development of Th1 and Thpopulation and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes[J]. J Immunol,1998,160:1320-1329
[18] Geissler M,Gesien A ,Tokushige K et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA based vaccines augmented with cytokine expressing plasmids[J]. J Immunol,1997,158:1231-1237
[19] van Beusechem V W , van Rijswijk A L, van Es H H ,et all Recombinant adenovirus vectors with knobless fibers for targeted gene transfer [J]. Gene Ther,2000,7 (22):1 940—1 946
[20] Nagao S , Kuriyama S , Okuda H , et all Adenovirus mediated gene transfer into tumors: evaluation of direct readminist ration of an adenoviral vector into subcutaneous tumors of immunocompetent mice [J]. Int JOncol, 2001,18(1):57-65
[1] Wang J, Michalak TI. Comparison of biological activity of recombinant woodchuck interferon gamma and tumor necrosis factor alpha produced in baculovirus and Escherichia coli expression systems[J]. Cytokine, 2005, 30(1):22-34
[2] Chun Xia, Wu Dan, Wu Wen-Xue, et al. Cloning and expression of interferon-a/β from a domestic porcine breed and its effect on classical swine fever virus[J]. Veterinary Immunology and Immunopathology, 2004, 104:81-89
[3] William A. Meier, Robert J. Husmann, William M. Schnitzlein,et al. Cytokines and synthetic double-stranded RNA augment the T helper 1 immune response of swine to porcine reproductive and respiratory syndrome virus[J]. Veterinary Immunology and Immunopathology, 2004, 102:299-314
[4] 曹瑞兵，周斌，陈溥言，等．猪γ-干扰素的基因克隆、改造、表达及其活性测定[J]．南京农业大学学报，2003，26(2)：71-75
[5] Chinaangaram J, Piccone M E. Ability of foot-and-mouth disease virus to form plaques in cell cultere is associated with suppression of alpha/beta interferon[J].J Vorol, 1999,73(12), 9891-8
[6] Chinsangaram J, Ko sterM, Grubman M J. Inhibition of L 2deleted foot-and-mouth disease virus replication by alphaobeta interferon involves double-stranded RNA-dependent protein kinase[J].J Virol, 2001, 75(12):5498-5503
[7] Chinsangaram J, M auro P M, Marla K, et al. Novel viral disease control strategy: adenovirus expressiong alpha interferon rapidly protects swine from foot-and-mouth disease[J]. J Virol, 2003, 77 (2): 1621-1625
[8] Q in X Q, Tao N,Dergary A, et al. Interferon-beta gene therpy inhibits tumor formation and causes regression of established tumors in immune-deficient mice[J]. Proc Natl Acad SciU SA, 1998, 95:14411-14416
[9] Mauro P. Moraes, Jarasvech Chinsangaram, Mario C.S. Brum, Marvin J. Grubman. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine[J]. Vaccine, 2003, 22:268-279
[1] Chinsangaram J, Beard C, Mason P W, et al. Antibody response in mice inoculated with DNA expressing Foot-and-mouth disease virus capsid proteins[J]. J Virol, 1998,72 (5): 4454-4457
[2] Jian-Zhong YI, Ming-Qiu LIU, Cai-Zhu ZHU, et al. Recombinant Bivalent Vaccine against Foot-and-Mouth Disease Virus Serotype O/A Infection in Guinea Pig[J]. Acta Biochimica et Biophysica Sinica, 2004,36(9):589-596
[3] Leticia Cedillo-Barron, Mildred Foster-Cuevas, Audra Cook, et al. Parkhouse. Immunogenicity of plasmids encoding T and B cell epitopes of foot-and-mouth disease virus (FMDV) in swine[J]. Vaccine, 2003, 21:4261-4269
[4] Belen Borrego, Paloma Fernandez-Pacheco, Llilianne Ganges, et al. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses[J]. Vaccine, 2006,24(18):3889-3899
[5] Luis L. Rodriguez, Jose Barrera, Ed Kramer, et al. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-0 VPl and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge[J]. Vaccine, 2003,21:3751-3756
[6] Yun-Gang Li, Fu-Lin Tian, Feng-Shan Gao, et al. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus[J]. Vaccine , 2007, 25(5):902-911
[7] Xi-Ju Shi, Bin Wang, Ming Wang. Immune enhancing effects of recombinant bovine IL-18 on foot-and-mouth disease vaccination in mice model.[J]. Vaccine, 2007, 25:1257-1264
[8] H. Mao, K.S. Rosenthal, An N-terminal arginine-rich cluster and a proline-alanine-threonine repeat region determine the cellular localization of the herpes simplex virus type 1 ICP34.5 protein and its ligand, protein phosphatase [J] J. Biol. Chem, 22002,77:11423-11431
[9] M. Prescott, S. Nowakowski, P. Nagley, et al. The length of polypeptide linker affects the stability of green fluorescent protein fusion proteins [J]. Anal. Biochem, 1999,273:305-307
[10] Emerman,M.&Temin, H.M. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism[J].Cell, 1984,39:449-469
[11] Mizuguchi H, Xu Z, I shii-Watabe A, et al. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in bicistronic vector[J]. Mol. Ther, 2000, 1:376-382
[12] Andrea L Szymczak, Creg J Workman, Yao Wang, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving'2A peptide-based retroviral vector[J].Nature biotechnology, 2004,22(5):589-595
[13] Kokuho T, Watanabe S, Yokamizo Y, et al. Production of biologically active, heterodimeric porcine interleukin-12 using a monocist romic baculoviral expression system[J]. Vet Immunol Immunopathol, 1999,72(3,4):289-302
[1] Yen H C, Bor L C. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by co-delivery of various cytokine genes [J]. The Immunology, 1998, 160:1320-1329
[2] Guo H, Chjen G, Lu F ,et al. Immunity induced by DNA vaccine of plasmid encoding the rhoptry protein gene combined with the genetic adjuvant of pc IFN-gamma against Tox oplasma gondi i in mice[J]. Chin M ed J, 2001, 114(3):317-320
[3] Nobiron I, Hompson I, Brownlie J, et al. Cytokine adjuvant of BVDV DNA vaccine enchances both humoral and cellular immune responses in mice[J]. Vaccine, 2001, 19(30):4226-4235
[4] Becker Y. Need for cellular and humoral immune responses in bovines to ensure protection from foot-and-mouth disease virus (FMDV) - a point of view[J]. Virus Genes, 1994, 8:199-214
[5] Francis M J, Hastings G Z, Syred A D, et al. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants[J]. Nature, 1987, 300:168-170
[6] Jun Zhao, Rebecca Voltan, Bo Peng et.al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag[J].Virology, 2005, 342:1-12
[2] Esteban Domingo, Eric Baranowski, Cristina Escarmi's Francisco Sobrino. Foot-and-mouth disease virus[J]. Microbiology & Infectious Diseases, 2002,25:297-308
[3] 江鹏斐，赵启祖，谢庆阁．口蹄疫研究进展[J]．中国农业科学，1999，32(6)：93～100
[4] 柳纪省．口蹄疫研究进展[J]．中国兽医科技．1999，29(3)：17-22
[5] 刘庆军，张永光．口蹄疫病毒基因组结构及其功能[J]．动物医学进展，2005，26(5)：1-5
[6] Martinez Salas E. Internal ribosome entry site biology and it s use in expression vector [J].Curr Opin Biotechnol, 1999, 10:458-464
[7] 卢曾军，刘在新．口蹄疫病毒研究概况[J]．中国兽医科技．2003,33(2)：69-74
[8] Stassinopoulos I A, Belsham GJ. A novel protein-RNA binding assay: functional interactions of the foot-and-mouth disease virus internal ribosome entry site with cellular proteins[J].RNA, 2001, 7(1):114-122
[9] Ohlmann T, Jackson R J. The properties of chimeric picornavirus IRESes show that internal translation initiation sites is influenced by the identity of the IRES and not just the context of the AUG codon[J]. RNA,1999,5(6):764-778
[10] Lopez de Quinto S, Lafuente E, Martinez-Salas E. IRES interaction wit h t ranslation initiation factors: functional characterization of novel RNA contact s wit h elF3, elF4B, and eIF4GⅡ[J]. RNA,2001,7(9):1213-1226
[11] Niepmann M. Effect s of potassium and chloride on ribosome association with the RNA of foot-and-mouth disease virus [J].Virus Res,2003,93(1):71-78
[12] Haydon D T, Samuel A R, Knowles N J. The generation and persistence of genetic variation in foot-and-mouth disease virus[J]. Prev Vet Med,2001,51: 111-124
[13] Marquardt O, Freiberg B. Antigenic variation among foot-and-mouth disease virus type A field isolates of 1997-1999 from Iran[J].Vet Microbiol,2000,74(4):377-386
[14] Araujo J P J r, Montassier H J, Pinto A A.Extensive antigenic and genetic variation among foot-and-mouth disease type A viruses isolated f rom the 1994 and 1995 foci in Sao Paulo , Brazil[J]. Vet Microbiol,2002,84(12):15-27
[15] PRATHAPAM TU,ASIRAM, MUDIT TYAGI, et al. Antigenic Variation in Foot and Mouth Disease Virus Type Asia 1 Isolates Circulated During 1993-95 in India[J].Virus Genes 1997,15(3):247-253
[16] Fares M A, Mora A, Escarmis C, etal. Evidence for positife selection in the capsid protein-coding region of the foot-and-mouth disease virus (FMDV) subjected to experimental passage regimens[J]. Mol Biol Evol,2001,18:10-21
[17] Manoj Kumar R, Sanyal A, Tosh C, et al. Mutation in the 1D gene (VP1) of foot-and-mouth disease virus serotype Asia I during serial cytolytic infections in cell culture[J].Arch Virol,2003,148(9):1815-1825
[18] 沈小燕，丛国正，常惠芸，等．口蹄疫病毒的抗原变异与逃避免疫反应[J]．中国兽医科技，2004，34(12)：33-37
[19] Butchaiah G, Morgan D O. Neutralization antigenic sites on type Asia-1 Foot-and-mouth disease virus defined by monoclonal antibody-resistant variants[J]. Virus Res,1997,52 (2):183-194
[20] Marquardt O, Rahman M M,Freiberg B. Genetic and antigenic variance of Foot-and-mouth disease virus type Asia-l[J]. Arch Virol,2000,145:149-157
[21] Zhang H Y, Sun S H, Guo Y J, et al. Immune response in mice inoculated with plasmid DNAs containing multiple-epitopes of Foot-and-mout h disease virus[J]. Vaccine,2003,21 (32):4704-4707.
[22] Blanco E, Briones G M, Sanz-Parra A,et al. Identification of T-cell epitopes in nonstructural proteins of Foot-and-mouth disease virus[J]. J Virol,2001,75(7):3164-3174
[23] Zhang Q, Yang Y Q, Zhang Z Y, et al. Immunogenicity of a recombinant fusion protein of tandem repeat epitopes of Foot-and-mouth disease virus type Asia 1 for guinea pigs[J]. Acta Virol,2002,46(1):1-9
[24] Schneider Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis[J].J Gen Virol, 2000, 81:1413-1429
[25] Baxt B, Neff S, Rieder E,et al. Foot-and-mouth disease virus-receptor interactions: Role in pathogenesis and tissue culture adsorption. In: Molecular Biology of Picronaviruses [P]. 2002, 115-123
[26] Jackson T, King A M, Stuart D I. Structure and receptor binding[J]. Virus Res, 2003, 91:33-46
[27] Wolfgang Ernst, Theresa Schinko, Alexandra Spenger, et al. Improving baculovirus transduction of mammalian cells by surface display of a RGD-motif[J]. Journal of Biotechnology, 2006, 126:237-240
[28] Jackson T, Mould A P, Sheppard D, et al. Integrin alphavbetal is a receptor for foot-and-mouth disease virus[J]. J Virol, 2002,76:935-941
[29] Leippert M, Beck E, Weiland F, et al. Point mutations within the G-H loop of foot-and-mouth disease virus O1K affect virus attachment to target cells[J]. J Virol,1997,71:1046-1051
[30] Duque H, Baxt B. Foot-and-mout h disease virus receptors: comparison of bovine alpha (V) integrin utilization by type A and O viruses[J]. J Virol,2003,77:2500-2511
[31] 沈小燕，常惠芸，丛国正，等．口蹄疫病毒感染细胞的研究进展[J]．动物医学进展，2005，26(6)：1-5
[32] 程泽华．口蹄疫的流行及其病毒的细胞受体[J]．畜禽业，2003，7：9
[33] Michael N, Anke P, Karsten M, et al. Functional involvement of polypyrinmidine tract-binding protein in translation iniation complexes with the internal ribosome entry site of foot-and-mouth virus[J]. J Virology,1997,71:8330～8339
[34] Lopez de Quinto S, Martinez2Salas E. Interaction of the elF4G initiation factor with the aphthovirus IRES is essential for internal translation initiation in vivo[J]. RNA,2000,6:1380-1392
[35] Belsham GJ, J ackson R J. Translation initiation on picornavirus RNA[M]. Translational Control of Gene Expression, New York Cold Spring Harbor Laboratory Press, Cold Spring Harbor:,2000,869-900
[36] Mason P W, Bezborodovan S V, Henry T M. Identification and characterization of a cisacting replication element (cre) adjacent to the IRES of foot-and-mout h disease virus[J]. J Virol,2002, 76:9686-9694
[37] Tiley L, King A M, Belsham G J. The foot-and-mout h disease virus cis-acting replication element (cre) can be complemented in trans within infected cells [J]. J Virol,2003, 77:2243-2246
[38] Nugent C I, Johnson K L, Sarnow P, et al. Functional coupling between replication and packaging of poliovirus replicon RNA[J]. J Virol,1999,73:427-435
[39] Sasaki J, Taniguchi K. The 5-end sequence of t he genome of Aichi virus, a picornavirus, contains an element critical for viral RNA encapsidation[J]. J Virol,2003,77:3542-3548
[40] Domingo E, Escarmis C, Baranowski E, et al. Evolution of foot-and-mout h disease virus[J]. Virus Res,2003,91:47-63
[41] 张海峰，富相奎．口蹄疫的流行与防制[J]．黑龙江农业科学2006，(1)：59～60
[42] 江鹏斐．口蹄疫研究进展[J]．中国农业科学，2000，(6)：93-100．
[43] 龚团莲，孙立杰，毛景东，等．口蹄疫研究概述[J]．内蒙古民族大学学报，2001，16(2)：393-396．
[44] Zinna, Kettlewell Hill. Foot and mouth disease[J]. Research in Veterinary Science, 2002, 73, 195-199
[45] Marvin J., Grubman, Barry Baxt. Foot-and-Mouth Disease[J].CLINICAL MICROBIOLOGY REVIEWS, 2004, 17(2):465-493
[46] 鲜思美，周碧君，文明，等．口蹄疫实验诊断技术研究进展[J]．山地农业生物学报，2006，25(1)：77～81
[47] 卢永干．用口蹄疫非结构蛋白鉴别康复动物与注射疫苗动物的研究及应用[J]．中国兽医科技，2000，30(10)：18-20
[48] 何永强，杜青云，盛祖恬，等．猪口蹄疫和水泡病病毒免疫鉴别诊断方法的比较[J]．中国预防兽医学报，1999，21(3)：228-230
[49] 朱彩珠，张强，常惠芸，等．NSP-ELISA鉴别口蹄疫病毒感染与免疫[J]．中国兽医科技，2004，33(8)：3-6
[50] M ezencio J M S, Babcock G D,M eyer R F, et al. Differentiating foot-and-mouth disease virus-infected from vaccinated animals with baculovirus-expressed specific proteins[J]. Vet Quart, 1998, 20(2):11-13
[51] Blanca Robiolo, Cristina Seki, Norberto Fondevilla, et al. Analysis of the immune response to FMDV structural and non-structural proteins in cattle in Argentina by the combined use of liquid phase and 3ABC-ELISA tests[J]. Vaccine, 2006,24:997-1008
[52] R.M. Armstrong, S.J. Cox, N. Aggarwal, et al. Detection of antibody to the foot-and-mouth disease virus (FMDV) non-structural polyprotein 3ABC in sheep by ELISA[J]. Journal of Virological Methods, 2005, 125:153-163
[53] Maria Gabriela Lopez, Andrea Peraltaa, Analia Berinsteina, et al. High-level expression of recombinant 3AB1 non-structural protein from FMDV in insect larvae[J]. Journal of Virological Methods, 2005, 124:221-224
[54] S. Parida, S.J. Cox, S.M. Reid, et al. The application of new techniques to the improved detection of persistently infected cattle after vaccination and contact exposure to foot-and-mouth disease[J]. Vaccine, 2005, 23(44): 5186-5195
[55] Jae Ku Oem, Byung Sik Chang, Hoo Don Joo. Development of an epitope-blocking-enzyme-linked immunosorbent assay to differentiate between animals infected with and vaccinated against foot-and-mouth disease virus [J]. Journal of Virological Methods, 2007,142:174-181
[56] B. Freiberg, B. Ho'" hlich, B. Haas, et al. Type-independentdetection of foot-and-mouth disease virus by monoclonal antibodies that bind to amino-terminal residues of capsid protein VP2[J]. Journal of Virological Methods, 2001, 92:199-205
[57] Ming Yang, Alfonso Clavijo, Mingyi Li, et al. Identification of a major antibody binding epitope in the non-structural protein 3D of foot-and-mouth disease virus in cattle and the development of a monoclonal antibody with diagnostic applications[J]. Journal of Immunological Methods, 2007, 321:174-181
[58] 蒋正军，尹燕博，龚振华，等．运用RT-PCR一步法和Nested-PCR法快速检测FMDV的研究[J]．中国动物检疫，1997，14，(2)：3-4
[59] 王伊琴，胡烈山，银泉，等．应用RT-PCR检测灭活疫苗中口蹄疫病毒(核酸)[J]．检验检疫科学，2003，13，(4)：48-49
[60] 朱彩珠，卢永干，邱孝高，等．应用反转录一聚合酶链反应检测口蹄疫病毒[J]．病毒学报，1998，14(3)：272-277
[61] 娄高明，杜伟贤，杨傲冰，等．应用RT-PCR技术检测动物组织中的口蹄疫病毒[J]．微生物学报，2002，29(4)：9-13
[62] 罗长保，鱼海琼，林志雄，等．应用荧光RT-PCR技术检测口蹄疫病毒[J]．中国兽医杂志，2003，39(12)：31
[63] Palani Giridharan, Divakar Hemadri, Chakradhar Tosh, et al. Development and evaluation of a multiplex PCR for differentiation of foot-and-mouth disease virus strains native to India[J]. Journal of Virological Methods, 2005, 126:1-11
[64] Jajati Keshari Mohapatra, Aniket Sanyal, Divakar Hemadri, et al. Development and comparison of genome detection assays for the diagnosis of foot-and-mouth disease suspected clinical samples[J]. Journal of Virological Methods, 2006, 137:14-20
[65] S. M. Reid, N. P. Ferris, G. H. Hutchings, et al. Diagnosis of foot-and-mouth disease by RT-PCR:use of phylogenetic data to evaluate primers for the typing of viral RNA in clinical samples[J]. Arch Virol, 2001, 146:2421-2434
[66] Thomas Bruun Rasmussen, A° se Uttenthal, Monserrat Agn"ero. Detection of three porcine vesicular viruses using multiplex real-time primer-probe energy transfer[J]. Journal of Virological Methods, 2006, 134:176-182
[67] 吕景福，陈橙，李邦佑，等．牲畜口蹄疫的综合防制[J]．湖北畜牧兽医，2005，2：37-38
[68] 田增义．口蹄疫的防制[J]．中国动物保健，2005，7：7-14
[1] 蒋文俊，李华春，李乐，等．口蹄疫疫苗研究进展[J]．畜牧与兽医，2004，36(5)：42-43
[2] 徐全武，申涛，马雪峰．口蹄疫疫苗研究进展[J]．新疆畜牧业，2003，3：47-48
[3] 王永录，张永光，方玉珍，等．牛O-A型口蹄疫双价灭活苗研究：效力试验和最小免疫剂量试验[J]．中国兽医科技，1999，29(9)：3-4
[4] V. Balamurugan, R. Renji, G. Venkatesh, et al. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant P1 polyprotein expressed in Pichia pastoris[J].Arch Virol, 2005, 150:967-979
[5] Jeng-Hwan Wang, Chi-Ming Liang, Jei-Ming Peng, et al. Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus[J].Vaccine, 2003,21:3721-3729
[6] Taboga O, Tami C, Carrillo E. et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants[J]. Virol, 1997, 71(4):2606-2614
[7] Judit Villen, Eliandre de Oliveira, Jose Ignacio Nunez, et al. Towards a multi-site synthetic vaccine to foot-and-mouth disease: addition of discontinuous site peptide mimic increases the neutralization response in immunized animals[J].Vaccine, 2004,22:3523-3529
[8] Eliandre de Oliveira, Miguel Angel Jimenez-Clavero, et al. Analysis of the immune response against mixotope peptide libraries from a main antigenic site of foot-and-mouth disease virus[J].Vaccine,2005,23:2647-2657
[9] Chinsangaram J, Beard C, Mason P W, et al. Antibody response in mice inoculated with DNA expressing Foot-and-mouth disease virus capsid proteins[J].J. Virol, 1998, 72 (5):4454-4457
[10] Jian-Zhong YI, Ming-Qiu LIU, Cai-Zhu ZHU, et al. Recombinant Bivalent Vaccine against Foot-and-Mouth Disease Virus Serotype O/A Infection in Guinea Pig[J]. Acta Biochemica et Biophysica Sinica 2004, 36(9): 589-596
[11] Leticia Cedillo-Barron, Mildred Foster-Cuevas, Audra Cook,Benito Gutiérrez-Castafieda, et al. Parkhouse. Immunogenicity of plasmids encoding T and B cell epitopes of foot-and-mouth disease virus (FMDV) in swine[J]. Vaccine, 2003, 21:4261-4269
[12] Belen Borrego, Paloma Fernandez-Pacheco, Llilianne Ganges, et al. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses[J]. Vaccine, 2006, 24(18):3889-3899
[13] V. Niborski, Y. Li, F. Brennan, et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV[J]. Vaccine, 2006, 24:7204-7213
[14] Fang Wang, Xiao-Wen He, Lei Jiang, et al. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice[J]. Vaccine, 2006, 24:2017-2026
[15] Yanmin Li, Neeraj Aggarwal, Haru-H. Takamatsu, et al. Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O[J]. Vaccine, 2006, 24:4602-4606
[16] Benvenisti L, Rogel A, Kuznetzova L, et al. Gene gun-mediate DNA vaccination against Foot-and-mouth disease virus[J].Vaccine, 2001, 19:3885-3895
[17] Wong H T, Cheng S C S, Chan E W C, et al. Plasmids encoding Foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J].Virology, 2000, 278:27-35
[18] 李光金，严维耀，徐泉兴，等．以猪IgG重链恒定区为抗原载体的抗口蹄疫病毒DNA疫苗的研制[J]．生物工程学报，2001，17(3)：322-324
[19] OSCAR TABOGA, CECILIA TAMI, ELISA CARRILLO, et al. A Large-Scale Evaluation of Peptide Vaccines against Foot-and-Mouth Disease:Lack of Solid Protection in Cattle and Isolation of Escape Mutants[J].JOURNAL OF VIROLOGY, 1997, Apr., 2606-2614
[20] 李光金，李颖杰，严维耀，等．CpG DNA增强口蹄疫病毒DN疫苗诱发豚鼠产生的免疫应答[J]．科学通报，2001，46(3)：477-480
[21] Wong H T, Cheng S C S, Sin F W Y, et al. A DNA vaccine against Foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J].Vaccine, 2002, 20:2641-2647
[22] Luis L. Rodriguez, Jose Barrera, Ed Kramer, et al. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge[J]. Vaccine,2003, 21:3751-3756
[23] Yun-Gang Li, Fu-Lin Tian, Feng-Shan Gao, et al. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus[J].Vaccine, 2007, 25(5):902-911
[24] Liang Chen, HanJuan Shao. Extract from Agaricus blazei Murill can enhance immune responses elicited by DNA vaccine against foot-and-mouth disease[J].Veterinary Immunology and Immunopathology, 2006,109:177-182
[25] Anne-Sophie Beignon, Fred Brown, Pierre Eftekhari, et al. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralizing anti-FMDV antibody responses[J]. Veterinary Immunology and Immunopathology, 2005,104:273-280
[26] Shieh J J ,Liang CM , Chen C Y, et al. Enhancement of the immunity to Foot-and-mouth disease virus by DNA priming and protein boosting immunization[J]. Vaccine, 2001,19: 4002-4010
[27] Huali Jin, Youmin Kang, Guoxing Zheng, et al. Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines[J]. Virology, 2005,337:183 -191
[28] Chan E W C, Wong H T, Cheng S C S, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine [J].Vaccine, 2001,19:538-546
[29] Guangjin Lia, Weizao Chena, Weiyao Yana, et al. Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or β-galactosidase as a carrier of immunogenic epitopes[J]. Virology, 2004,328:274-281
[30] Sreerupa Challa, Roger Barrette, Debra Rood, et al. Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus.[J]. Vaccine, 2007,25:3328-3337
[31] Baranowski E, Ruiz-jarabo C M, Sevilla N, et al. Cell Recognition by Foot-and-mouth disease uirus That lacks the RGD Integrin-Binding Motif: Flexibility in Aphthovirus Receptor Usage[J]. J Virol, 1999,73:2739-2744
[32] Ping Qian, Xiang-Min Li, Mei-Lin Jin, et al. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine[J]. Vaccine, 2004, 22:2129-2136
[33] Sanz-Parra A, Uazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor poly peptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80:671-679
[34] Min Zheng, Ningyi Jin, Hongyong Zhang, et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease viras[J]. Journal of Virological Methods, 2006,136:230-237
[35] Berinstein A, Tami C, Taboga O, et al. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus[J]. Vaccine, 2000,18:2231-2238
[36] G. A. Mayr, Jarasvech Chinsangaram, Marvin J. Grubman Development of Replication-Defective Adenovirus Serotype 5 Containing the Capsid and 3C Protease Coding Regions of Foot-and-Mouth Disease Virus as a Vaccine Candidate[J]. Virology, 1999, 263:496-506
[37] G. A. Mayr, O'Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus- FMDV constructs[J]. Vaccine, 2001,19:2152-2162
[38] Mauro P. Moraes, Jarasvech Chinsangaram, Mario C.S. Brum, et al. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine[J]. Vaccine, 2003,22:268-279
[39] Juan M. Pacheco, Mario C.S. Brum, Mauro P. Moraes, et al. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vector FMDV subunit vaccine[J]. Virology, 2005, 337 205-209
[40] Sonia de Avila Botton, Mario C.S. Brum, Elida Bautista, et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha.[J]. Vaccine, 2006, 24:3446-3456
[41] N. Gomez, C.Carrillo, J. Salinas, et al. Expression of Immunogenic Glycoprotein S Polypeptides from Transmissible Gastrenteritis Coronavirus in Transgenic Plants[J].Virology 1998, 249(2):352-358
[42] Dong-Mei He, Kai-Xian Qian, Gui-Fang Shen, et al . Stable expression of foot-and-mouth disease virus protein VP1 fused with cholera toxin B subunit in the potato (Solarium tuberosum) [J]. Colloids and Surfaces B: Biointerfaces, 2007,55:159-163
[43] Wigdorovitz A.,D.M.Perez Filgueira, C. Carrillo, et al. Protection of mice against challenge with foot and mouth disease with foliar exacts from plants infected with recombinant tobacco mosaic virus expressing th FMDV structural protein VP1[J].Virology, 1999,264:85-91
[44] Lubin Jiang, Qiaoli Li, Mangmang Li, et al. A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco[J]. Vaccine, 2006, 24:109-115
[45] Carrillo C, Wgdorovitz A, Oliveros C, et al. Protective immune response to foot and mouth disease virus with VP1 expressed in transgenic plants[J].J Virol,1998,72:1688-1690
[46] C. Carrillo, A. Wigdorovitz, K. Trono, et al. Induction of a virus specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants[J]. Viral Immunol, 2001,14:49-57
[47] Wigdorovitz A, Carrillo C, Dus Santos MJ,et al.Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein[J]. Virol, 1999, 255(2):347-353
[48] Mar'ia J. Dus Santos, Consuelo Carrillo, Fernando Ardila, et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen[J]. Vaccine, 2005, 23:1838-1843
[49]余云舟,王罡,金宁一,等．口蹄疫病毒结构蛋白P1基因转化玉米的初步研究[J]．玉米科学,2004,12(3)：22—25
[50] 李昌，金宁一，王罡，等．口蹄疫病毒P1全长基因表达载体的构建及对马铃薯的转化[J]．吉林农业大学学报，2004，26(5)：507-510
[51] 李文建，沈明山，李春江，等．口蹄疫抗原决定簇融合基因转化胡萝卜的研究[J]．厦门大学学报(自然科学版)，2005，44：154-157
[52] 倪志华，张红心，王鸣刚，等．口蹄疫抗原决定簇融合基因转化水稻的研究[J]．厦门大学学报(自然科学版)，2005，44：158-1
[1] 卢曾军，刘在新．口蹄疫病毒研究概况[J]．中国兽医科技，2003，33(2)：69-74
[2] Esteban Domingo, Eric Baranowski, Cristina Escarmi's Francisco Sobrino. Foot-and-mouth disease virus[J]. Comparative Immunology, Microbiology & Infectious Diseases, 2002, 25:297-308
[3] Zinna, Kettlewell Hill. Foot and mouth disease[J]. Research in Veterinary Science 2002, 73:195-199
[4] Marvin J. Grubman, Barry Baxt. Foot-and-Mouth Disease[J].CLINICAL MICROBIOLOGY REVIEWS, 2004, 17(2):465-493
[5] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆试验指南，第二版，1999：49-52
[6] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆试验指南，第二版，1999：19-21
[7] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆实验指南，第二版，1999：845-888
[1] 江鹏斐，赵启祖，谢庆阁．口蹄疫研究进展[J]．中国农业科学，1999，32(6)：93-100
[2] Hong-Ying Zhang,Shu-Han Sun,Ying-Jun Guo,et al. Immune response in mice inoculated with plasmid DNAs containing multiple-epitopes of foot-and-mouth disease virus[J]Vaccine 2003,21:470-4707
[3] Wong HT, Cheng SCS,Chan EWC,et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J].Virology,2000,278:27～35
[4] 欧阳立明，张惠展，张嗣同．巴斯德毕赤酵母的基因表达系统研究进展[J]．生物化学与生物物理进展2000，27(2)：151-154
[5] 彭毅，杨希才，康良仪．影响甲醇酵母外源蛋白表达的因素[J]．生物技术通报，2000，4：33-36
[6] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯．分子克隆试验指南[M]，第二版，1999，24-28
[7] 剧海，梁东春，郭刚，等．用于PCR实验的毕赤酵母基因组DNA制备方法的比较[J]．天津医药．2003，31(5)：270-272
[8] Beard C,Ward G,Rieder E,et al. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine [J].J.Biotechnol,1999,73(223):243—249
[9] ASEA A,KRAEFT SK, JONES EAK, et aI.HSP70 stimulate cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine[J].Nature Medicine,2000,4:435-436
[10] Udono H,Yamano T,Kawabata Yet al. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70[J].Inter Immunol, 2001, 13(10): 1233-1242
[11] Planelles L, Thomas MC, Alonso C, et al. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMPll protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection[J]. Infect Immun 2001;69:6558-6563
[12] 杨晟，黄鹤，章如安．重组人血清蛋自在Pichia pastoris中分泌表达影响因素的研究[J]生物工程学报2000，16(6)：675-678
[13] EasySelect Pichia Expression Kit, Catalog no.K1740-01, Invitrogen
[1] 卢曾军，刘在新．口蹄疫病毒研究概况[J]．中国兽医科技，2003，33(2)：69-74
[2] Tami C, Farber M, Palma E L, et al. Presentation of antigenic sites from foot-and-mouth disease virus on the surface of baculovirus and in the membrane of infected cells.[J].Arch Virol, 2000, 145(9): 1815-1828
[3] Mayr GA, O'Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs[J].Vaccine, 2001, 19(15-16):2152-2162
[4] Cox S J, Barnett P V, Dani P, et al. Emergency vaccination of sheep against foot and mouth disease: Protection against disease and reduction in contact transmission[J]. Vaccine, 1999, 17(15-16):1858-1868
[5] Wigdorovitz A, Perez Filgueira D M. Protection of mice against challenge with foot and mouth disease virus(FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1[.J]Virology, 1999, 264(1): 85-91
[6] Berinstein A, Tami C, Taboga O, et al. Protective immunity against foot-and-mouth disease virus induced by a recombinant vaccinia virus[J]. Vaccine, 2000, 18(21): 2231-2238
[7] Grubman M J, Baxt B. Foot-and-Mouth Disease[J]. Clinical Microbiol, 2004, 17:465-493.
[8] 李光金，李颖杰，严维耀，等．CpG DNA增强口蹄疫病毒DNA疫苗诱发豚鼠产生的免疫应答[J]．科学通报，2001，46(3)：477-480
[9] Wong H T, Cheng S C S, Sin F W Y, et al. A DNA vaccine against Foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J]. Vaccine, 2002, 20:2641-2647
[10] ASEA A,KRAEFF SK,JONES EAK, et al.HSP70 stimulate cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine[J].Nature Medicine,2000,4:435-436
[1] Wong HT, Cheng SC, Chan EW, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J]. Virology, 2000, 278(1):27-35
[2] Hohlich B J, Wiesmuller KH, Haas B, et al. Induction of an antigenspecific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B-cell epitopes[J].J Gen Virol 2003,84(12):3315-3324
[3] Sanz-Parra A, Vazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80(P3):671-679
[4] Sanz-Parra A, Jimenez-Clavero M A, Garcia-Briones M M, et al. Recombinant viruses expressing the foot-andmouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology, 1999, 259(1):129-134
[5] Garcia-Briones M M, Blanco E, Chiva C, et al. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D[J]. Virology, 2004, 322(2):264-275
[6] Ping Qian, Xiang-Min Li, Mei-Lin Jin, et al. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine[J]. Vaccine 22 (2004) 2129-2136
[7] Sanz- Parra A, Uazquez B, Sobrino F, et al. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor poly peptide (P1) of foot-and-mouth disease virus capsid proteins[J]. J Gen Virol, 1999, 80:671-679
[8] A lexander J, F ikes J, Hoffman S, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development [J]. Immuno 1 Res, 1998, 18:79-92
[9] Crouzet J, Naudin L, Orsinic C, et al. Recombinational construction in Escherichia coli of infections adenovirual genomes[J].Proc Natl Acad Sci USA, 1997, 94:14
[10] T C He, S Zhou, L T Costa, et al. A simplified system for generating recombinant adenovirnses[J]. Proc Nail Acad Sci USA, 1998, 95:2509-2514
[1] Gaff en SL, Liu KD. Overview of interleukin-2 function, production and clinical applications[J]. Cytokine, 2004, 7, 28 (3):109-123
[2] At kins MB, Kunkel L, Sznol M, et al. High-dose recombinant intedeukin-2 therapy in patients with metastatic melanoma: long term survival update[J]. Cancer J Sci Am, 2000, 6 (Suppl1): 11-14
[3] Hyung Joon Cha, Hwa Sung Shin, Hye Jung Lim, et al. Comparative production of human interleukin-2 fused with green fluorescent protein in several recombinant expression systems[J]. Biochemical Engineering Journal, 2005, 24:225-233
[4] James P. McGettigan, Martin L. Koser, Philip M. McKenna,et al. Enhanced humoral HIV-l-specifc immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2[J]. Virology, 2006, 344:363-377
[5] Yann Pellequer, Michel Ollivon, Gillian Barratt. Formulation of liposomes associated with recombinant intedeukin-2: effect on interleukin-2 activity[J]. Biomedicine & Pharmacotherapy, 2004, 58:162-167
[6] Rashika E1 Ridi, Rabab Salem, Areal Wagih. Influence of interleukin-2 and interferon-gamma in murine Schistosomiasis[J]. Cytokine, 32006, 3:281-288
[7] L.V. Cherenova, D.Y. Logunov, E.V. Shashkova. Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo[J]. Virus Research, 2004, 100:257-261
[8] John H. Wyckoff Ⅲ, Jeri L. Howland, Catherine M. O'Connell Scott, et al. Recombinant bovine interleukin-2 enhances immunity and protection induced by Brucella abortus vaccines in cattle[J]. Veterinary Microbiology, 2005, 111:77-87
[9] Silja A° vall-Ja"a"skela"inen, Airi Palva. Secretion of biologically active porcine interleukin-2 by Lactococcus lactis[J]. Veterinary Microbiology, 12006, 15:278-283
[10] Ho-Tsun Wong, Samuel Chak-Sum Cheng, et al. A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2[J]. Vaccine, 2002, 20:2641-2647
[11] Yan Lin, He Qigai, Yu Xiaolan, et al. The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs[J]. Vaccine, 2005, 23:4436-4441
[12] Shashi A. Gujar, Tomasz I. Michalak .Characterization of bioactive recombinant woodchuck interleukin-2 amplified by RLM-RACE and produced in eukaryotic expression system[J]. Veterinary Immunology and Immunopathology, 2006,112:183-198
[13] Ji-Yong Zhou, Jin-Yong Wang, Ji-Gang Chen, et al Cloning, in vitro expression and bioactivity of duck interleukin-2[J]. Molecular Immunology, 2005,42:589-598
[14] Maria C. Denis, Brigitte T. Huber. Native and recombinant interleukin-2, two functionally distinct molecules[J]. Molecular Immunology, 2003, 40:279-286
[15] KimJ J ,Trivedi N N ,Nottingham L K et al . Modulation of amplitude and direction of in vivo immune responses by co- administration of cytokine gene expression cassettes with DNA immunogens[J]. Eur J Immunol,1998, 28:1089-1093
[16] Chow Y H , Huang W L ,Chi W K et al. Improvement of hepatitis B virus DNA vaccines by plasmids co-expressing hepatitis B surface antigen and interleukine-2[J]. J Virol,1997, (1):169-178
[17] Chow Y H ,Chiang B L ,Lee YL et al. Development of Th1 and Thpopulation and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes[J]. J Immunol,1998,160:1320-1329
[18] Geissler M,Gesien A ,Tokushige K et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA based vaccines augmented with cytokine expressing plasmids[J]. J Immunol,1997,158:1231-1237
[19] van Beusechem V W , van Rijswijk A L, van Es H H ,et all Recombinant adenovirus vectors with knobless fibers for targeted gene transfer [J]. Gene Ther,2000,7 (22):1 940—1 946
[20] Nagao S , Kuriyama S , Okuda H , et all Adenovirus mediated gene transfer into tumors: evaluation of direct readminist ration of an adenoviral vector into subcutaneous tumors of immunocompetent mice [J]. Int JOncol, 2001,18(1):57-65
[1] Wang J, Michalak TI. Comparison of biological activity of recombinant woodchuck interferon gamma and tumor necrosis factor alpha produced in baculovirus and Escherichia coli expression systems[J]. Cytokine, 2005, 30(1):22-34
[2] Chun Xia, Wu Dan, Wu Wen-Xue, et al. Cloning and expression of interferon-a/β from a domestic porcine breed and its effect on classical swine fever virus[J]. Veterinary Immunology and Immunopathology, 2004, 104:81-89
[3] William A. Meier, Robert J. Husmann, William M. Schnitzlein,et al. Cytokines and synthetic double-stranded RNA augment the T helper 1 immune response of swine to porcine reproductive and respiratory syndrome virus[J]. Veterinary Immunology and Immunopathology, 2004, 102:299-314
[4] 曹瑞兵，周斌，陈溥言，等．猪γ-干扰素的基因克隆、改造、表达及其活性测定[J]．南京农业大学学报，2003，26(2)：71-75
[5] Chinaangaram J, Piccone M E. Ability of foot-and-mouth disease virus to form plaques in cell cultere is associated with suppression of alpha/beta interferon[J].J Vorol, 1999,73(12), 9891-8
[6] Chinsangaram J, Ko sterM, Grubman M J. Inhibition of L 2deleted foot-and-mouth disease virus replication by alphaobeta interferon involves double-stranded RNA-dependent protein kinase[J].J Virol, 2001, 75(12):5498-5503
[7] Chinsangaram J, M auro P M, Marla K, et al. Novel viral disease control strategy: adenovirus expressiong alpha interferon rapidly protects swine from foot-and-mouth disease[J]. J Virol, 2003, 77 (2): 1621-1625
[8] Q in X Q, Tao N,Dergary A, et al. Interferon-beta gene therpy inhibits tumor formation and causes regression of established tumors in immune-deficient mice[J]. Proc Natl Acad SciU SA, 1998, 95:14411-14416
[9] Mauro P. Moraes, Jarasvech Chinsangaram, Mario C.S. Brum, Marvin J. Grubman. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine[J]. Vaccine, 2003, 22:268-279
[1] Chinsangaram J, Beard C, Mason P W, et al. Antibody response in mice inoculated with DNA expressing Foot-and-mouth disease virus capsid proteins[J]. J Virol, 1998,72 (5): 4454-4457
[2] Jian-Zhong YI, Ming-Qiu LIU, Cai-Zhu ZHU, et al. Recombinant Bivalent Vaccine against Foot-and-Mouth Disease Virus Serotype O/A Infection in Guinea Pig[J]. Acta Biochimica et Biophysica Sinica, 2004,36(9):589-596
[3] Leticia Cedillo-Barron, Mildred Foster-Cuevas, Audra Cook, et al. Parkhouse. Immunogenicity of plasmids encoding T and B cell epitopes of foot-and-mouth disease virus (FMDV) in swine[J]. Vaccine, 2003, 21:4261-4269
[4] Belen Borrego, Paloma Fernandez-Pacheco, Llilianne Ganges, et al. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses[J]. Vaccine, 2006,24(18):3889-3899
[5] Luis L. Rodriguez, Jose Barrera, Ed Kramer, et al. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-0 VPl and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge[J]. Vaccine, 2003,21:3751-3756
[6] Yun-Gang Li, Fu-Lin Tian, Feng-Shan Gao, et al. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus[J]. Vaccine , 2007, 25(5):902-911
[7] Xi-Ju Shi, Bin Wang, Ming Wang. Immune enhancing effects of recombinant bovine IL-18 on foot-and-mouth disease vaccination in mice model.[J]. Vaccine, 2007, 25:1257-1264
[8] H. Mao, K.S. Rosenthal, An N-terminal arginine-rich cluster and a proline-alanine-threonine repeat region determine the cellular localization of the herpes simplex virus type 1 ICP34.5 protein and its ligand, protein phosphatase [J] J. Biol. Chem, 22002,77:11423-11431
[9] M. Prescott, S. Nowakowski, P. Nagley, et al. The length of polypeptide linker affects the stability of green fluorescent protein fusion proteins [J]. Anal. Biochem, 1999,273:305-307
[10] Emerman,M.&Temin, H.M. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism[J].Cell, 1984,39:449-469
[11] Mizuguchi H, Xu Z, I shii-Watabe A, et al. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in bicistronic vector[J]. Mol. Ther, 2000, 1:376-382
[12] Andrea L Szymczak, Creg J Workman, Yao Wang, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving'2A peptide-based retroviral vector[J].Nature biotechnology, 2004,22(5):589-595
[13] Kokuho T, Watanabe S, Yokamizo Y, et al. Production of biologically active, heterodimeric porcine interleukin-12 using a monocist romic baculoviral expression system[J]. Vet Immunol Immunopathol, 1999,72(3,4):289-302
[1] Yen H C, Bor L C. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by co-delivery of various cytokine genes [J]. The Immunology, 1998, 160:1320-1329
[2] Guo H, Chjen G, Lu F ,et al. Immunity induced by DNA vaccine of plasmid encoding the rhoptry protein gene combined with the genetic adjuvant of pc IFN-gamma against Tox oplasma gondi i in mice[J]. Chin M ed J, 2001, 114(3):317-320
[3] Nobiron I, Hompson I, Brownlie J, et al. Cytokine adjuvant of BVDV DNA vaccine enchances both humoral and cellular immune responses in mice[J]. Vaccine, 2001, 19(30):4226-4235
[4] Becker Y. Need for cellular and humoral immune responses in bovines to ensure protection from foot-and-mouth disease virus (FMDV) - a point of view[J]. Virus Genes, 1994, 8:199-214
[5] Francis M J, Hastings G Z, Syred A D, et al. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants[J]. Nature, 1987, 300:168-170
[6] Jun Zhao, Rebecca Voltan, Bo Peng et.al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag[J].Virology, 2005, 342:1-12